1	Enrichment analyses identify shared associations for 25 quantitative
2	traits in over 600,000 individuals from seven diverse ancestries
3 4 5 6	Samuel Pattillo Smith <sup>1,2</sup> , Sahar Shahamatdar <sup>1,2</sup> , Wei Cheng <sup>1,2</sup> , Selena Zhang <sup>1</sup> , Joseph Paik <sup>1</sup> , Misa Graff <sup>3</sup> , Christopher Haiman <sup>4</sup> , T.C. Matise <sup>5</sup> , Kari E North <sup>3</sup> , Ulrike Peters <sup>6</sup> , Eimear Kenny <sup>7,8,9,10</sup> , Chris Gignoux <sup>11</sup> , Genevieve Wojcik <sup>12</sup> , Lorin Crawford <sup>1,13,14,*</sup> , and Sohini Ramachandran <sup>1,2,*,†</sup>
7 8 9 10 11 12 13	<ul> <li><sup>1</sup>Center for Computational Molecular Biology, Brown University, Providence RI</li> <li><sup>2</sup>Department of Ecology and Evolutionary Biology, Brown University, Providence RI</li> <li><sup>3</sup>Department of Epidemiology, University of North Carolina - Chapel Hill, Chapel Hill NC</li> <li><sup>4</sup>Department of Preventative Medicine, University of Southern California, Los Angeles CA</li> <li><sup>5</sup>Department of Genetics, Rutgers University, Piscataway NJ</li> <li><sup>6</sup>Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle WA</li> <li><sup>7</sup>The Center for Genomic Health, Icahn School of Medicine at Mount Sinai, New York City</li> </ul>
14	NY 8The Charles Developer Institute for Devendent Medicine, Jacky School of Medicine et
15 16	<sup>8</sup> The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York City NY
10 17 18 19	<sup>9</sup> Department of Medicine, Icahn School of Medicine at Mount Sinai, New York City NY <sup>10</sup> Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York City NY
20	<sup>11</sup> Division of Biomedical Informatics and Personalized Medicine, University of Colorado,
21	Denver CO
22	<sup>12</sup> Department of Epidemiology, Johns Hopkins University, Baltimore MD <sup>13</sup> Department of Biostatistics, Brown University, Providence RI
23	<sup>14</sup> Microsoft Research New England, Cambridge MA
24 25	*indicates these authors contributed equally
26	<sup>†</sup> To whom correspondence should be addressed: sramachandran@brown.edu
27	<sup>‡</sup> Present address: 164 Angell Street, Floor 3, Providence, RI 02906
28	Last edited November 3, 2021
29	Abstract

30	Since 2005, genome-wide association (GWA) datasets have been largely biased toward sampling Euro-
31	pean ancestry individuals, and recent studies have shown that GWA results estimated from self-identified
32	European individuals are not transferable to non-European individuals due to various confounding chal-
33	lenges. Here, we demonstrate that enrichment analyses which aggregate SNP-level association statistics
34	at multiple genomic scales—from genes to genomic regions and pathways—have been underutilized in the
35	GWA era and can generate biologically interpretable hypotheses regarding the genetic basis of complex

trait architecture. We illustrate examples of the robust associations generated by enrichment analy-36 ses while studying 25 continuous traits assayed in 566,786 individuals from seven diverse self-identified 37 human ancestries in the UK Biobank and the Biobank Japan, as well as 44,348 admixed individuals 38 from the PAGE consortium including cohorts of African-American, Hispanic and Latin American, Na-39 40 tive Hawaiian, and American Indian/Alaska Native individuals. We identify 1,000 gene-level associations that are genome-wide significant in at least two ancestry cohorts across these 25 traits, as well as highly 41 conserved pathway associations with triglyceride levels in European, East Asian, and Native Hawaiian 42 cohorts. 43

# 44 Introduction

<sup>45</sup> Over the past two decades, funding agencies and biobanks around the world have made enormous invest-<sup>46</sup> ments to generate large-scale datasets of genotypes, exomes, and whole-genome sequences from diverse <sup>47</sup> human ancestries that are merged with medical records and quantitative trait measurements <sup>1–8</sup>. However, <sup>48</sup> analyses of such datasets are usually limited to the application of standard genome-wide association (GWA) <sup>49</sup> SNP-level association analyses, in which SNPs are tested one-by-one for significant association with a phe-<sup>50</sup> notype <sup>9–11</sup> (Table 1). Yet, even in the largest available multi-ancestry biobanks, GWA analyses fail to offer <sup>51</sup> a comprehensive view of genetic trait architecture among human ancestries.

<sup>52</sup> SNP-level GWA results are difficult to interpret across multiple human ancestries due to a litany of <sup>53</sup> confounding variables, including: (*i*) ascertainment bias in genotyping<sup>2,5</sup>, (*ii*) varying linkage disequilib-<sup>54</sup> rium (LD) patterns<sup>12,13</sup>, (*iii*) variation in allele frequencies due to different selective pressures and unique <sup>55</sup> population histories<sup>13-17</sup>, and (*iv*) the effect of environmental factors on phenotypic variation<sup>18-21</sup>. These <sup>56</sup> confounders and the observed low transferability of GWA results across ancestries<sup>2,22,23</sup> have generated <sup>57</sup> an important call for increasing GWA efforts focused on populations of diverse, non-European ancestry <sup>58</sup> individuals.

We also note, as other studies have  $^{6,24}$ , that the GWA SNP-level test of association is rarely applied to 59 non-European ancestry individuals<sup>25</sup>. There are two likely explanations for leaving non-European ancestry 60 individuals out of analyses: (i) researchers are electing to not analyze diverse cohorts due to a lack of 61 statistical power and concerns over other confounding variables (recently covered in Ben-Eghan et al.<sup>24</sup>); or 62 (ii) the analyses of non-European cohorts yield no genome-wide significant SNP-level associations. In either 63 case, valuable information is being ignored in GWA studies or going unreported in resulting publications<sup>24–26</sup>. 64 Even when diverse ancestries are analyzed, GWA studies usually condition on GWA results identified using 65 European ancestry cohorts to detect and give validity to other SNP-level associations<sup>6</sup>. In our own analysis 66

of abstracts of publications between 2012 and 2020 using UK Biobank data, we found that only 33 out of 166 67 studies (19.87%) reported genome-wide significant associations in any non-European ancestry cohort (Figure S1 - Figure S2). Focusing energy and resources on increasing GWA sample sizes without intentional focus 69 on sampling of non-European populations will thus likely perpetuate an already troubling history of leaving 70 non-European ancestry samples out of GWA analyses of large-scale biobanks such as the UK Biobank<sup>24</sup> 71 (but see Sinnott-Armstrong et al.<sup>27</sup>). However, we note that non-European ancestry GWA studies have 72 and will continue to have — smaller sample sizes than existing and emerging European-ancestry GWA 73 cohorts, limiting the precision of effect size estaimates in these studies. What has received less attention than 74 the need to improve GWA study design is the potential of enrichment analyses to characterize genetic trait 75 architecture in multi-ancestry datasets while accounting for variable statistical power to detect, estimate, 76 and replicate genetic associations among cohorts. 77

In this analysis, we illustrate that focusing solely on p-values from the standard GWA framework is 78 insufficient to capture the genetic architecture of complex traits. Specifically, we propose that expansion of 79 association analyses to the genomic scale of genes and pathways generates robust and interpretable hypothe-80 ses about trait architecture in multi-ancestry cohorts. These enrichment analyses can increase the power to 81 detect genes through the aggregation of SNPs of small effect (which explain the majority of the heritability 82 of most traits<sup>28,29</sup>). Mathieson<sup>30</sup> recently highlighted the pattern of homogeneity of direction of effect in 83 multi-ancestry studies even when individual SNPs are not categorized as genome-wide significant in multiple 84 ancestries. Gene and pathway level analyses can prioritize biological regions where there is homogeneity in 85 the direction of effect, generating biologically interpretable hypotheses for the genetic architecture of complex 86 traits in multiple ancestry cohorts. 87

In this study of 25 quantitative traits and more than 600,000 diverse individuals from the UK Biobank 88 (UKB), BioBank Japan (BBJ), and the PAGE study data (Table S1 - Table S9), we detail biological insights 89 gained from the application of gene and pathway level enrichment analyses to seven diverse ancestry cohorts. 90 We perform genetic association tests for SNPs, genes, and pathways across multiple ancestry groups with 91 a trait of interest. We test for significantly mutated subnetworks of genes using known protein-protein in-92 teraction networks and the Hierarchical HotNet software<sup>31</sup>. Enrichment analyses do not require generating 93 additional information beyond standard GWA inputs (or outputs, for methods that take in GWA summary 94 statistics). We demonstrate that moving beyond SNP-level associations allows for a biologically comprehen-95 sive prioritization of shared and ancestry-specific mechanisms underlying genetic trait architecture.

# 97 Materials and Methods

#### <sup>98</sup> Data overview

<sup>99</sup> We performed statistical tests of association at the SNP, gene, and pathway-level for 25 quantitative traits. <sup>100</sup> These analyses were performed on data seven ancestry cohorts drawn from the UK Biobank, BioBank Japan <sup>101</sup> (BBJ), and PAGE consortia (Table S3). Descriptions of the samples studied, including sample size, and <sup>102</sup> number of SNPs for each ancestry cohort are given in Table S1 and Table S4 - Table S9. For an extensive <sup>103</sup> description of each cohort from the three biobanks that we analyze in this study, see the Supplemental <sup>104</sup> Information.

#### <sup>105</sup> SNP-level GWA analyses

In the European, African, and South Asian ancestry cohorts from the UK Biobank, we performed GWA 106 studies for each ancestry-trait pair in order to test whether the same SNP(s) are associated with a given 107 quantitative trait in different ancestries. SNP-level GWA effect sizes were calculated using plink and the 108 --glm flag<sup>32</sup>. Age, sex, and the first twenty principal components were included as covariates for all traits 109 analyzed<sup>7</sup>. Principal component analysis was performed using flashpca  $2.0^{33}$  on a set of independent markers 110 derived separately for each ancestry cohort using the plink command --indep-pairwise 100 10 0.1 . 111 Summary statistics for the 25 quantitative traits in the Biobank Japan, as well as available ancestry-trait 112 pairs in the PAGE study data, were then compared with the results from the association analyses in the UK 113 Biobank cohorts (same traits as listed in Table S4). In each analysis of an ancestry-trait pair, a separate 114 Bonferonni-corrected significance threshold was calculated using the number of SNPs tested in that particular 115 ancestry-trait pair (Table S10). 116

#### <sup>117</sup> Comparison of SNP level fine-mapping methods and effect size direction

We compared the results of two fine-mapping methods, SuSie<sup>34</sup> and PESCA<sup>35</sup>, when applied to SNP-level summary statistics in the European (UKB) and East Asian (BBJ) cohorts. SuSie is an iterative Bayesian stepwise selection method that identifies a credible set of SNPs that contribute to a phenotype of interest<sup>34</sup>. Using the effect sizes and standard errors generated from the standard GWA framework for each trait in each ancestry, we applied SuSiE in order to identify probable sets of causal SNPs. We then found the correlation between the posterior inclusion probabilities of each SNP in the European and East Asian cohorts (Table S11 - Table S13).

<sup>125</sup> Unlike SuSiE, the PESCA framework is explicitly designed for identifying shared SNP-level association

signals between multiple ancestry cohorts versus ancestry-specific associations  $^{35}$ . In addition to GWA sum-126 mary statistics, PESCA uses information about the correlation structure between SNPs (i.e., LD) to identify 127 SNPs that are likely to be causal in two cohorts of interest. Shi et al.<sup>35</sup> analyzed seven continuous traits in 128 the European (UKB) and East Asian (BBJ) cohorts using PESCA and produced posterior probabilities that 129 individual SNPs were: (i) associated with a phenotype in both the both cohorts, (ii) associated with the 130 trait of interest only in the European cohort, or *(iii)* associated with the trait of interest only in the East 131 Asian cohort. For each trait, we calculated the number of SNPs that were nominally significant (p-value 132  $< 10^{-5}$ , as in the original PESCA analysis) in the standard GWA framework in both the European and 133 East Asian cohorts and had a PESCA posterior probability of being associated in both ancestries > 0.8 (see 134 Table S14). We also found the number of SNPs that had a PESCA posterior probability of being associated 135 in both ancestries > 0.8 that were only identified as significant in one ancestry using the GWA framework. 136 Finally, we explored the recent proposition of Mathieson<sup>30</sup> that the direction of effect for SNP-level 137 summary statistics might be conserved among ancestry cohorts even if those variants are not genome-wide 138 significant in either cohort. To that end, for each of the 25 traits that we analyzed, we compared the direction 139 of SNP effect sizes between the European and East Asian ancestry cohorts. We were only able to carry this 140 analysis out for variants that were genotyped in both cohorts (Table S14). For each remaining nominally 141 significant variant, we stored the direction of the effect size and checked the direction of effect size in the other 142 ancestry. When zero was included within the range of the effect size plus or minus one standard deviation. 143 we assumed the SNP did not have the same direction in both cohorts. The results of our comparison are 144 shown in Table S14. We note that this test may be confounded by the precision of effect size estimation and 145 warrants further exploration, including an analysis of local false sign discovery rates (see  $^{36,37}$ ). 146

#### <sup>147</sup> Gene-level association tests

In order to test aggregated sets of SNP-level GWA effect sizes for enrichment of associated mutations with 148 a given quantitative trait, we applied gene- $\varepsilon^{38}$  to each ancestry cohort we studied for each trait of interest, 149 resulting in 125 sets of gene-level association statistics (Table S3, Table S15). The gene- $\varepsilon$  method takes two 150 summary statistics as input: (i) SNP-level GWA marginal effect size estimates  $\hat{\beta}$  derived using ordinary least 151 squares and (*ii*) an LD matrix  $\Sigma$  empirically estimated from external data (e.g., directly from GWA study 152 genotype data, a matrix estimated from a population with similar genomic ancestry to that of the samples 153 analyzed in the GWA study). It is well-known that SNP-level effect size estimates can be inflated due to 154 various correlation structures among genome-wide genotypes. gene- $\varepsilon$  uses its inputs to derive regularized 155 effect size estimates through elastic net penalized regression. 156

In practice, gene- $\varepsilon$  and other enrichment analyses<sup>39–41</sup> can be applied to any user-specified set of genomic 157 regions, such as regulatory elements, intergenic regions, or gene sets. These gene-level association tests enable 158 identifying traits in which genetic architecture may be heterogeneous among individuals at the SNP-level 159 across individuals; applying gene- $\varepsilon$  in multiple ancestry cohorts allows researchers to further test whether 160 genes associated with a trait of interest are the same, or vary, across ancestries. gene- $\varepsilon$  takes as input a list 161 of boundaries for all regions to be tested for enrichment of associations. In our study, we applied gene- $\varepsilon$  to all 162 genes and transcriptional elements defined in Gusev et al.<sup>42</sup> for human genome build 19. Throughout this 163 study, we refer to the resulting effect size estimates produced by gene- $\varepsilon$  as "gene-level association statistics". 164 In our gene-level analysis, SNP arrays included both genotyped and high-confidence imputed SNPs (in-165 formation score  $\geq 0.8$ ) for each ancestry-trait pair. To compute the LD matrix, we first pruned highly linked 166 SNPs so that the number of SNPs included for any chromosome was less than 35,000 SNPs — the computa-167 tional limit of gene- $\varepsilon$  due to the size of the LD matrix — using the plink command --indep-pairwise 100 10 0.5. 168 For the UK Biobank European, South Asian, and African ancestry cohorts, we then derived empirical LD es-169 timates between each pair of SNPs for each chromosome in each cohort using plink flag --r square applied 170 to the empirical genotype and high-confidence imputed data. The ancestry-specific SNP arrays were then 171 used to calculate 23,603 gene-level association statistics for the European ancestry cohort, 23,671 gene-level 172 association statistics for the South Asian ancestry cohort, and 23,575 gene-level association statistics for the 173 African ancestry cohort. 174

To calculate gene-level association statistics using Biobank Japan summary statistics, we first found the 175 intersection between SNPs included in the analysis of each trait (Table S4) and SNPs included in the 1000 176 Genomes Project phase 3 data for the sample of 93 JPT individuals. Note, this intersection was different 177 among some traits as the genotype data in the Biobank Japan were from different studies, which in turn used 178 different genotyping arrays. We then pruned highly linked markers for each trait separately using the plink 179 flag --indep-pairwise 100 10 X where X was determined by finding the highest possible value that led 180 to less than 35,000 SNPs being included on each chromosome for the trait. Because of the increased density 181 of SNPs with effect size estimates for Height, X was set to prune more conservatively at X = 0.15. For all 182 other traits, X was set to 0.5. The number of regions for which a gene- $\varepsilon$  gene-level association statistic was 183 calculated for each trait is given in Table S4. 184

GWA summary statistics for the five cohorts in the PAGE study data were used as input to gene- $\varepsilon$ for each available ancestry-trait combination. The array of markers for each ancestry cohort in the PAGE study data was pruned using plink flag --indep-pairwise 100 10 X. X was set to the maximum value in each ancestry that ensured no chromosome contained more than 35,000 markers: X was set to 0.05 for the African-American cohort, 0.08 for the Hispanic and Latin American and AIAN cohorts, and 0.25 for

the Native Hawaiian cohorts. Finally, for each ancestry-trait combination, genes that passed the Bonferroni corrected *p*-value (p = 0.05/number of genes tested) were labeled as "significant" throughout this study (see Table S15 for specific thresholds).

#### <sup>193</sup> Pathway analysis and network propagation using Hierarchical HotNet

We tested for shared and divergent gene-level association results among interacting genes for each trait 194 of interest using network propagation of gene- $\varepsilon$  gene-level association statistics as input to Hierarchical 195 HotNet<sup>31</sup>. Hierarchical HotNet identifies significantly altered subnetworks using gene-level scores as input; 196 in this study, these gene scores were set to  $-\log_{10}$ -transformed p-values of gene- $\varepsilon$  gene-level association test 197 statistics (see also Nakka et al.  $^{41}$ ,  $^{43}$ ). For each ancestry-trait combination, we assigned *p*-values of 1 to genes 198 with p-values greater than 0.1 to make the resulting networks both sparse and more interpretable (again see 199 Nakka et al.  $^{41}, ^{43}$ ). In addition, ancestry-trait pairs in which less than 25 genes produced gene- $\varepsilon$  p-values 200 less than 0.1 were discarded as there were an insufficient number of gene-level statistics to populate the 201 protein-protein interaction networks. 202

We used three protein-protein interaction networks: ReactomeFI 2016<sup>44</sup>, iRefIndex 15.0<sup>45</sup>, and HINT+HI<sup>46,47</sup>. For the ReactomeFI 2016 interaction network, interactions with confidence scores less than 0.75 were discarded. The HINT+HI interaction network consists of the combination of all interactions in HINT binary, HINT co-complex, and HuRI HI interaction networks. We ran Hierarchical HotNet (10<sup>3</sup> permutations) on the thresholded  $-\log_{10}$ -transformed gene-level *p*-values for each ancestry-trait combination. We restricted our further investigation to the largest subnetwork identified in each significant ancestry-trait-interaction network combination (p < 0.05).

#### 210 **Results**

# SNP-level replication of GWA results among ancestries is the exception, not the rule

Multiple recent studies have interrogated the extent to which SNP-level associations for a given trait replicate across ancestries, both empirically and under a variety of models (see Wojcik et al.<sup>6</sup>, Durvasula and Lohmueller<sup>22</sup>, Shi et al.<sup>35</sup>, Carlson et al.<sup>48</sup>, Liu et al.<sup>49</sup>, Eyre-Walker<sup>50</sup>, Shi et al.<sup>51</sup>). To extensively compare variant-level associations among the seven ancestry cohorts that we analyzed, we first examined the number of genome-wide significant SNP-level associations that replicated exactly based on chromosomal position and rsID in multiple ancestries (see Figure S3a and Figure S3c, with Bonferroni-corrected thresholds

provided in Table S10). Exact replication of at least one SNP-level association across two or more ancestries 219 occurs in all 25 traits that were studied. The C-reactive protein (CRP) trait had the highest proportion of 220 replicated SNP associations in multiple ancestries, with 18.95% replicating using the standard GWA frame-221 work in at least two ancestries, but has a relatively low number of unique GWA significant SNPs (2,734) 222 when compared to other traits (Figure 1). This is likely because the genetic architecture of CRP is sparse 223 and highly conserved across ancestries, as is shown in Figure 2. We note that the concordance of genome-224 wide significant SNP-level association statistics for CRP among five ancestry cohorts is exceptional. In the 225 other 24 traits we analyzed, we did not observe any SNP-level replication among five cohorts. C-reactive 226 protein, which is encoded by the gene of the same name located on chromosome 1, is synthesized in the 227 liver and released into the bloodstream in response to inflammation. In our standard GWA analysis of SNP-228 level association signal in each ancestry cohort with CRP, rs3091244 is genome-wide significant in a single 229 ancestry cohort. rs3091244 has been functionally validated as influencing C-reactive protein levels  $5^{2,53}$  and 230 is linked to genome-wide significant SNPs in the other two ancestries for which genotype data is available. 231 Interestingly, all GWA significant SNP-level associations for CRP in the Native Hawaiian ancestry cohort 232 replicate in both the African-American (PAGE) and the Hispanic and Latin American cohorts (these three 233 cohorts were all genotyped on the same array). 234

In the other 24 traits, the proportion of genome-wide SNP-level replications was below 10% (Figure 1a). For polygenic traits, replication of SNP-level GWA results is challenging to interpret considering the large number of GWA significant associations for the trait overall. For example, height contains the largest number of replicated SNP-level associations in our multi-ancestry analysis — but these only represent 8.90% of all unique SNP-level associations with height discovered in any ancestry cohort. A more comprehensive discussion of previously associated SNPs is available for both height and CRP in the Supplemental Information.

# Fine-mapping methods have variable efficacy in identification of SNP level asso ciations among ancestry cohorts

Often, replication of GWA results across cohorts is tested using genomic regions centered on a SNP. Scans across the region surrounding the SNP of interest are usually defined arbitrarily — using physical windows (or "clumps") to smooth over ascertainment bias and varying LD across cohorts or ancestries instead of using regions that are biologically annotated such as genes or transcriptional elements. While clumping presents an easy way to scan for regional replication of a given GWA finding, the corresponding results are not readily interpretable when prioritizing GWA results for downstream validation. We performed clumping

using windows of size 1Mb centered around significant SNP-level associations (see Materials and Methods). 250 Height had the largest proportion of windows that contain a SNP-level association that replicated in at least 251 two ancestries (Figure S3b and Figure S3e). In the three traits with the greatest proportion of windows 252 containing SNP-level replications — height (77.09% of clumps), urate (65.89%), and low density lipoprotein 253 (54.40%) — we then recorded the number of genes and transcriptional elements within the window that 254 contained GWA significant SNP-level associations. We found that for all three traits, the vast majority of 255 1Mb windows that were used to clump SNP-level associations contained multiple genes and transcriptional 256 elements with significantly associated SNPs: height  $(94.04\%, 17.93 \text{ genes in clump (mean)} \pm 15.71 \text{ (standard)})$ 257 deviation)), urate (97.47%, 18.44  $\pm$  13.72), and low density lipoprotein (99.12%, 14.85  $\pm$  12.89). Thus, we 258 find window-based clumping does not easily produce biologically interpretable hypotheses for downstream 259 validation. 260

Recent analyses of multi-ancestry GWA cohorts have also tested for effect size heterogeneity <sup>6,34,51,54,55</sup>. 261 We applied the fine-mapping method  $SuSiE^{34}$  to identify signals of effect size heterogeneity in the three 262 ancestry cohorts for which we had access to raw genotype data (UK Biobank European ancestry, African 263 ancestry, and South Asian ancestry individuals; see Table S1). We find little evidence of correlated SuSiE 264 effect size estimates among ancestry cohorts, including among independent subsamples of the UK Biobank 265 European ancestry individuals Table S11 - Table S13. In addition, we applied PESCA (a method developed 266 by Shi et al.<sup>51</sup>) to the results of our SNP-level analysis to understand how the modeling of LD to affected the 267 power to identify probably causal SNPs shared in the European and East Asian ancestry cohorts. PESCA 268 improves upon standard clumping approaches by modeling the LD in a region to identify SNPs that are 269 likely to be causal for the same trait in multiple ancestries. In a comparison with the results from seven 270 continuous traits analyzed in the original study 51, we found that the vast majority of SNPs identified by 271 PESCA as causal (posterior probability > 0.8) in both ancestries were also nominally significant in our SNP-272 level association results (see Table S14). Both SuSiE<sup>34</sup> and PESCA<sup>51</sup> demonstrate the utility of modeling 273 variation in LD structure among ancestries when conducting multi-ancestry GWA studies. 274

Recently, Mathieson<sup>30</sup> proposed the hypothesis that the direction of effect sizes is the same among 275 ancestries, even when the effects are not genome-wide significant. To test this, we compared the direction 276 of effect in SNPs that were significant in either the European or East Asian ancestry cohort to the direction 277 of the effect in the other ancestry where the SNP was tested using the standard GWA framework. We limit 278 the comparison to the European and East Asian cohorts due to their large sample sizes which increases the 279 precision of effect size estimates. Table S14 shows the number of variants that were significantly associated 280 with each trait in at least one of the European and East Asian ancestry cohorts, and also displays the number 281 of those variants that have the same direction of effect as the significant variant in the other ancestry. In 282

the 25 traits that we analyzed, the direction of effect was conserved in both the European and East Asian 283 ancestry cohorts (between effect direction concordance from 55.87% and 76.56% of SNPs across 25 traits). 284 The remaining SNPs where the direction of the effect size was not conserved represent those SNPs that: 285 (i) had different direction of effect size, (ii) were not tested in both ancestry cohorts, or (iii) had effect 286 size estimates within one standard error of zero (Table S14). The observed conservation of effect size 287 direction in multiple ancestry cohorts, even when SNPs are non-significant in one or more cohorts, is a 288 primary assumption of regional enrichment methods and supports Mathieson<sup>30</sup>'s hypothesis and findings. 289 This suggests that regional enrichment methods, which are sensitive to shared patterns of effect size direction 290 among cohorts, are a natural approach to apply to GWA summary statistics even in the absence of replication 291 SNP-level GWA signals among cohorts. 292

#### <sup>293</sup> Valuing biological mechanism over statistical significance

Enrichment analyses aggregate SNP-level association statistics using predefined SNP sets, genes, and path-294 ways to identify regions of the genome enriched for trait associations beyond what is expected by chance. 295 Published enrichment analyses have demonstrated the ability to identify trait associations that go unidenti-296 fied when using standard SNP-level GWA analysis<sup>38,40,56–60</sup>. The standard GWA method is known to have 297 a high false discovery rate (FDR)<sup>36,61</sup>, which enrichment analyses can mitigate. Our analyses in Figure S4 298 and Figure S5 illustrate that two methods — regression with summary statistics  $(RSS)^{60}$ , a fully Bayesian 299 method; and gene- $\varepsilon^{38}$  — control FDR particularly well both in the presence and absence of population struc-300 ture. Enrichment methods also increase power for identifying biologically interpretable trait associations in 301 studies with smaller sample sizes than present-day GWA studies. For example, Nakka et al.<sup>41</sup> identified 302 an association between ST3GAL3 and attention deficit hyperactivity disorder (ADHD) using methods that 303 aggregated SNP-level signals across genes and networks. ADHD is a trait with heritability estimates as high 304 as 75% which had no known genome-wide significant SNP-level associations at the time: Nakka et al.<sup>41</sup> 305 studied genotype data from just 3.319 individuals with cases, 2.455 controls and 2.064 trios  $^{62}$ . A study by 306 Demontis et al.<sup>63</sup> later found a SNP-level association in the ST3GAL3 gene, but was only able to do so 307 with a cohort an order of magnitude larger (20.183 individuals diagnosed with ADHD and 35,191 controls, 308 totaling 55,374 individuals). 309

Because non-European GWA ancestry cohorts usually have much smaller sample sizes compared to studies with individuals of European ancestry, enrichment analyses offer a unique opportunity to boost statistical power and identify biologically relevant genetic associations with traits of interest using multiancestry datasets. In a simulation study using synthetic phenotypes generated from the European and

African ancestry cohorts in the UK Biobank, we show that gene- $\varepsilon$  is able to identify significantly associated 314 genes even in smaller cohorts (N = 10,000 and N = 4,967 in the European and African ancestry cohorts, 315 respectively) without the inflated false discovery rate that is often exhibited by the standard GWA framework 316 (Figure S6 and Figure S7). Additionally, in these simulations, gene- $\varepsilon$  correctly identifies "causal" genes that 317 are commonly associated in both cohorts (Figure S8 and Figure S9). These simulations illustrate the utility 318 of modeling LD (and in the case of gene- $\varepsilon$ , additionally shrinking inflated effect sizes) information to identify 319 enrichment of SNP-level associations in predefined SNP sets. 320

In an analysis performed by Ben-Eghan et al.<sup>24</sup> on 45 studies analyzing UK Biobank data, the second 321 most commonly stated reason for omitting non-European cohorts in applied GWA analyses was due to lack of 322 power for identifying SNP-level GWA signals. We tested for gene-level associations in each of the 25 complex 323 traits in each ancestry cohort for which we had data (Table S1 - Table S9), and identified associations in 324 genes and transcriptional elements shared across ancestries for every trait. All of our analyses discussed here 325 used gene- $\varepsilon$  (see performance comparison with other enrichment analyses in Cheng et al.<sup>38</sup> and Figure S6 326 - Figure S9), an empirical Bayesian approach that aggregates SNP-level GWA summary statistics, where 327 p-values for each gene are derived by constructing an empirical null distribution based on the eigenvalues 328 of a gene-specific partitioning of the LD matrix (for more details, see Cheng et al.<sup>38</sup>). Our analyses show 329 that several hematological traits have a higher rate of significant gene-level associations that replicate across 330 multiple ancestry cohorts than SNP-level associations that replicate across ancestry cohorts (Figure 1b). 331 These include platelet count (PLC), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin 332 concentration (MCHC), hematocrit, hemoglobin, mean corpuscular volume (MCV), red blood cell count 333 (RBC), and neutrophil count (Figure S3f). Focusing on platelet count as an example, we identify 65 genes 334 that are significantly enriched for associations in multiple ancestries when tested using gene- $\varepsilon$  (see Table S15 335 for details on Bonferroni thresholds used to correct for the number of genes tested)<sup>38</sup>. Fifty-five of these 336 genes are significantly associated in both the European and East Asian ancestry cohorts, and the remaining 337 ten all replicate in other pairs of ancestry cohorts. Overall, each of the six ancestry cohorts in our analysis 338 share at least one significant gene with another ancestry cohort, as shown in Figure S10. 339

Results from gene-level enrichment analyses can be further propagated on protein-protein interaction 340 networks to identify interacting genes enriched for association signals<sup>64</sup>. Often, studies use network propa-341 gation as a way to incorporate information from multiple "omics" databases in order to identify significantly 342 mutated gene subnetworks or modules contributing to a particular disease  $^{65}$ . An unexplored extension 343 of network propagation is how it can be used with multi-ancestry GWA datasets to identify significantly 344 mutated subnetworks that are shared or ancestry-specific<sup>43</sup>. 345

346

To conduct network propagation of gene-level association results in our analyses, we applied the Hier-

archical HotNet method<sup>31</sup> to gene- $\varepsilon$  gene-level association statistics for each trait-ancestry data set. In 3, 347 we display the significant (p-value < 0.01) network results for triglyceride levels in three ancestry cohorts: 348 European, East Asian, and Native Hawaiian (networks separated by ancestry are available in Figure S11). 349 In both the European and East Asian cohorts, we identify enrichment of mutations in a highly connected 350 subnetwork of genes in the apolipoprotein family. In addition, we identify a gene subnetwork enriched for 351 mutations in the East Asian and Native Hawaiian cohorts that interacts with the significantly mutated sub-352 network identified in both the European and East Asian cohorts. For instance, beta-secretase 1 (BACE1), 353 is a genome-wide significant gene-level association in the East Asian cohort but does not contain SNPs 354 previously associated with triglycerides in any ancestry cohort in the GWAS catalog. Additionally, both 355 APOL1 and HBA1 were identified as significantly associated with triglycerides using gene- $\varepsilon$  in our analysis 356 of the Native Hawaiian ancestry cohort, and both genes were part of significant subnetworks identified by 357 Hierarchical HotNet in the European and Native Hawaiian ancestry cohorts. Details on replicated SNP-level 358 and gene-level associations among ancestries for triglyceride levels are shown in Figure S12 and Figure S13, 359 respectively. SNP-level and gene-level association results are further discussed for both platelet count and 360 triglyceride levels in the Supplemental Information. 361

#### 362 Discussion

Many recent studies have proposed changes to multi-ancestry GWA study design<sup>2,5,6,22,24–27,66,67</sup>. In this 363 analysis, we have focused on the potential of *methods* to increase the insight gained into complex trait archi-364 tecture from multi-ancestry GWA datasets via the generation of biologically interpretable hypotheses. We 365 demonstrate the potential gains of moving beyond standard SNP-level GWA analysis using 25 quantitative 366 complex traits among seven human ancestry cohorts in three large biobanks: BioBank Japan and the UK 367 Biobank, and the PAGE consortium database (Table S1 - Table S9). Ultimately, we believe that complex 368 traits demand analysis across multiple genomic scales and ancestries in order to gain biological insight into 369 complex trait architecture and ultimately achieve personalized medicine. 370

As has been previously noted <sup>5,25</sup>, non-European ancestry cohorts are often excluded from GWA analyses of multi-ancestry biobanks; complementing the analyses of Ben-Eghan et al. <sup>24</sup>, we find that 80.13% of UK Biobank studies over the last 9 years only report significant SNP-level associations in the white British cohort (Figure S1 - Figure S2), despite the tens of thousands of individuals of non-European ancestry sampled in that data set. Unless this practice is curbed by the biomedical research community, it will exacerbate already existing disparities in healthcare across diverse communities. There are undoubted benefits from increased sampling in a given ancestry for association mapping using the standard GWA framework, but it is still

<sup>378</sup> unknown the extent to which results from larger GWA and fine-mapping studies using European-ancestry <sup>379</sup> genomes will generalize to the entire human population <sup>2,20</sup>.

Here, we have not addressed the downstream consequences of using self-identified ancestry to define 380 cohorts in large-scale GWA studies (but see Urbut et al.<sup>37</sup>, Willer et al.<sup>68</sup>, Lin et al.<sup>69</sup>, Yang et al.<sup>70</sup>). 381 Each sample we analyzed has also experienced environmental exposures that may influence the statistical 382 detection of genetic associations, and some of those environmental exposures may be correlated with genomic 383 ancestry<sup>13,71–73</sup>. Interrogation of the influence of gene by environment interactions on complex traits must 384 be done with highly controlled experiments, which can in turn help prioritize traits in which association 385 studies will be interpretable and useful. Increasing sample size in GWA studies alone will not resolve these 386 fundamental biological questions: the proportion of phenotypic variance explained by associations discovered 387 as sample sizes increase in GWA studies has largely reached diminishing returns<sup>39</sup>, and gene by environment 388 interactions are increasingly influential, and estimable, in large biobanks with cryptic relatedness<sup>74,75</sup>. 389

Many recent methodological advances that leverage GWA summary statistics have focused on: testing 390 the co-localization of causal SNPs (e.g., fine mapping <sup>34,54,76,77</sup>); the non-additive effects of SNP-level inter-391 actions (i.e., epistasis<sup>78,79</sup>); and multivariate GWA tests<sup>37,79–81</sup>. While these methods can be extended and 392 applied to multi-ancestry GWA analyses, they still focus on SNP-level signals of genetic trait architecture 303 (see also Brown et al.<sup>82</sup>, Galinsky et al.<sup>83</sup>). Unlike the traditional GWA method, enrichment analyses 394 increase statistical power by aggregating SNP-level signals of genetic associations and allowing for genetic 395 heterogeneity in SNP-level trait architecture across samples, as well as offering the opportunity for immedi-396 ate insights into trait architecture using existing datasets. However, these methods have been comparatively 397 underused in multi-ancestry GWA studies. 398

While many studies note that differences in LD across ancestries affect transferability of effect size estimates<sup>6,48,84–86</sup>, recent studies in population genetics have additionally debated how various selection pressures and genetic drift may hamper transferability of GWA results across ancestries (see for example, Edge and Rosenberg<sup>15,16</sup>, Novembre and Barton<sup>18</sup>, Harpak and Przeworski<sup>20</sup>, Durvasula and Lohmueller<sup>22</sup>, Mostafavi et al.<sup>23</sup>). Future GWA studies should be coupled with approaches from studies of how evolutionary processes shape the genetic architecture of complex traits<sup>20,28,50,87</sup>.

Two open questions must be tackled when studying complex trait architecture in the multi-ancestry biobank era: (i) to what extent is the true genetic trait architecture (causal SNPs and/or their effects on a trait of interest) heterogeneous across cohorts?<sup>6,88</sup> and (ii) which components of GWA results (e.g. pvalues, estimated effect size, direction of effect sizes) are transferable across ancestries, at any genomic scale? Continued application of the standard SNP-level GWA approach will not answer these questions. However, enrichment methods that aggregate SNP-level effects, test for effect size heterogeneity, leverage genomic

<sup>411</sup> annotations and gene interaction networks offer opportunities to directly test these fundamental questions.
<sup>412</sup> Methods can and should play an important role as biomedical research shifts current paradigms to extend
<sup>413</sup> the benefits of personalized medicine beyond people of European ancestry.

Additionally, biomedical researchers should continue to pressure both funding agencies and institutions to diversify their sampling efforts in the name of inclusion and addressing—instead of exacerbating—genomic health disparities. In addition to those efforts, we believe existing and new methods can increase the return on investment in multi-ancestry biobanks, ensure that every bit of information from these datasets is studied, and prioritize biological mechanism above SNP-level statistical association signals by identifying associations that are robust across ancestries.

# 420 Appendices

<sup>421</sup> Detailed information about the SNP-level results for both C-reactive protein and height, as well as, gene <sup>422</sup> and pathway level associations for platelet count and triglyceride levels can be found in the Appendix.

#### 423 Declaration of interests

C.G. owns stock in 23andMe. E.E.K. and C.G. are members of the scientific advisory board for Encompass
Bioscience. E.E.K. consults for Illumina.

#### 426 Acknowledgments

We thank Kirk Lohmueller and Alicia R. Martin for helpful comments on an earlier version of this manuscript. 427 as well as the Crawford and Ramachandran Labs for helpful discussions. This research was conducted in 428 part using computational resources and services at the Center for Computation and Visualization at Brown 429 University as well as, using the UK Biobank Resource under Application Number 22419. The Population 430 Architecture Using Genomics and Epidemiology (PAGE) program is funded by the National Human Genome 431 Research Institute (NHGRI) with co-funding from the National Institute on Minority Health and Health Dis-432 parities (NIMHD). The WHI program is funded by the National Heart, Lung, and Blood Institute, National 433 Institutes of Health, U.S. Department of Health and Human Services through contracts 75N92021D00001, 434 75N92021D00002, 75N92021D00003, 75N92021D00004, 75N92021D00005. The HCHS/SOL study was car-435 ried out as a collaborative study supported by contracts from the National Heart, Lung and Blood Institute 436 (NHLBI) to the University of North Carolina (N01-HC65233), University of Miami (N01-HC65234), Albert 437

Einstein College of Medicine (N01-HC65235), Northwestern University (N01-HC65236) and San Diego State
University (N01-HC65237). S.P.S. is a trainee supported under the Brown University Predoctoral Training
Program in Biological Data Science (NIH T32 GM128596). L.C. acknowledges the support of an Alfred
P. Sloan Research Fellowship and a David & Lucile Packard Fellowship for Science and Engineering. This
work was also supported by US National Institutes of Health R01 GM118652 to S.R., and S.R. acknowledges
additional support from National Science Foundation CAREER Award DBI-1452622.

# 444 Web Resources

- The methods applied in this paper include: PESCA (https://github.com/huwenboshi/pesca), RSS(https:
- //github.com/stephenslab/rss), gene- $\varepsilon$  (https://github.com/ramachandran-lab/genee), and Hierar-
- chical HotNet (https://github.com/raphael-group/hierarchical-hotnet).

# 448 Data and code availability

All scripts, publicly available data, and outputs from GWA, gene, and pathway association tests are avail-

- able at https://github.com/smithsap/redefining\_replication. Results from PESCA analyses were
- <sup>451</sup> provided through personal correspondence with Huwenbo Shi.

# 452 Figures and Tables

Genomic Scale	Association Test	Model of Genetic Trait Architecture	Relevant Example	
SNPs	Standard univariate genome-wide association (GWA) test	The true mutation-level trait architecture is the same for all individuals.	Many inflammatory bowel disease mutations replicate across ancestries <sup>49</sup> .	
SNP-Sets/Genes	Gene-level association tests (e.g., gene- $\varepsilon^{38}$ , SKAT <sup>40</sup> )	Core genes are the same across all ancestries, with potentially varying causal SNPs.	Late-onset Alzheimer's disease risk from $ApoE4$ allele is lower in African ancestry individuals <sup>89</sup> .	
Pathways/Networks	Pathway analysis and network propagation (e.g., Hierarchical HotNet <sup>31</sup> , RSS <sup>60</sup> ).	Core genes differ across ancestries, but are all in the same annotated pathway.	Skin pigmentation architecture in the same pathway differs between African and European ancestry individuals <sup>2</sup> .	

**Table 1: The three genomic scales and corresponding association tests used in this study.** The models of genetic trait architecture corresponding to each genomic scale and statistical method that have been previously invoked in the literature (including relevant examples cited in the last column). These nested genomic scales should routinely be leveraged in multi-ancestry GWA studies to generate biologically interpretable hypotheses of trait architecture across ancestries.

Trait	Number of significant SNPs in at least the European or East Asian cohort	Number of SNPs with same direction of effect	Percentage of SNPs with same direction of effect
BMI	6,374	4,456	69.91
Basophil	884	520	58.82
CRP	694	463	66.71
Cholesterol	3,451	2,379	68.94
DBP	1,962	1,320	67.28
EGFR	7,129	5,038	70.67
Eosinophil	5,890	3,608	61.26
HBA1C	3,030	2,206	72.81
HDL	5,995	4,077	68.01
Height	33,577	22,090	65.79
Hematocrit	5,382	3,602	66.93
Hemoglobin	5,280	3,601	68.20
LDL	2,521	1,929	76.56
Lymphocyte	2,214	1,237	55.87
MCH	6,763	4,674	69.11
MCHC	1,760	1,124	63.86
MCV	7,489	5,208	69.54
Monocyte	3,929	2,565	65.28
Neutrophil	5,431	3,850	70.89
PLC	11,014	7,161	65.02
RBC	9,211	6,263	67.99
SBP	1,807	1,182	65.41
Triglyceride	3,743	2,686	71.76
WBC	6,017	4,105	68.22
Urate	5,864	3,787	64.58

Table 2: Effect size homogeneity in variants identified as significant in the European or East Asian cohorts. In each of the 25 traits analyzed in this study a majority of variants that are significant in at least the European or East Asian cohorts had the same direction of effect in the other ancestry cohort.




Figure 1: Less stringent significance thresholds lead to a decrease in the proportion of replicated SNP-level associations and an increase in the proportion of gene-level associations among ancestries for each of the 25 traits analyzed. a. Proportion of all SNP-level Bonferroni-corrected genome-wide significant associations in any ancestry that replicate in at least one other ancestry is shown on the x-axis (see Table S10 for ancestry-trait specific Bonferroni corrected *p*-value thresholds). On the y-axis we show the proportion of significant gene-level associations that were replicated for a given phenotype in at least two ancestries (see Table S15 for Bonferroni corrected significance thresholds for each ancestry-trait pair). The black stars on the x- and y-axes represent the mean proportion of replicates in SNP and gene analyses, respectively. C-reactive protein (CRP) contains the greatest proportion of replicated SNP-level associations of any of the phenotypes. b. The x-axis indicates the proportion of SNP-level associations that surpass a nominal threshold of p-value  $< 10^{-5}$  in at least one ancestry cohort that replicate in at least one other ancestry cohort. The y-axis indicates the proportion of gene-level associations that surpass a nominal threshold of p-value  $< 10^{-3}$  in at least one ancestry cohort and replicate in at least one other ancestry cohort. Nominal *p*-value thresholds tend to decrease the proportion of replicated SNP-level associations and tend to increase the proportion of replicated gene-level associations. The number of unique SNPs and genes that replicated in each cohort is given in Figure S15. c. The x-axis indicates the proportion of SNP-level associations that surpass a nominal threshold of p-value  $< 10^{-3}$  in at least one ancestry cohort that replicate in at least one other ancestry cohort. The y-axis indicates the proportion of gene-level associations that surpass a nominal threshold of p-value  $< 10^{-2}$  in at least one ancestry cohort and replicate in at least one other ancestry cohort. The number of unique SNPs and genes that replicated in each cohort is given in Figure S16. As shown in panel **b**, nominal *p*-value thresholds tend to decrease the proportion of replicated SNP-level associations and tend to increase the proportion of replicated gene-level associations. Expansion of three letter trait codes are given in Table S2 and a version of this plot with all trait names displayed as text is shown in Figure S14. Figure S14 shows the same set of plots with all traits represented as text.




Figure 2: C-reactive protein is an exceptional trait where standard GWA analyses may be sufficient to identify shared genetic architecture among ancestry cohorts. a. Manhattan plot for SNP-level associations with C-reactive protein levels. Ancestry-specific Bonferroni-corrected significance thresholds are shown with dashed horizontal grey lines and listed in Table S10. Note that the scale of the  $-\log_{10^-}$  transformed *p*-values on the y-axis is different for each ancestry for clarity. **b.** Manhattan plot of SNP-level associations around the CRP gene located on chromosome 1 for each ancestry (zoomed in from panel a). Boundaries of the CRP gene are shown with vertical dashed black lines. All six ancestries contain genome-wide significant SNPs in the region. Black stars in the European, South Asian, and East Asian plots represent rs3091244, a SNP that has been functionally validated as contributing to serum levels of C-reactive protein<sup>52,53</sup>. c. Heatmap of Bonferroni-corrected significant genotyped SNPs replicated between each pair of ancestries analyzed. Here, we focus on SNPs in the 1MB region surrounding the CRP gene. Entries along the diagonal represent the total number of SNP-level associations in the 1MB region surrounding the CRP gene for each ancestry. The color of each cell is proportional to the percentage of SNP-level associations replicated out of all possible replications in each ancestry pair (i.e., the minimum of the diagonal entries between the pairs being considered). For example, the maximum number of genome-wide significant SNPs that can possibly replicate between the Hispanic and East Asian is 25, and 20 replicate resulting in the cell color denoting 80% replication. A similar matrix, computed including imputed SNPs is shown in Figure S17.





Figure 3: A subnetwork of apolipoprotein genes is significantly enriched for mutations in European, East Asian, and Native Hawaiian ancestries associated with triglyceride levels. The largest significantly altered subnetwork (p-value < 0.05) for triglyceride levels contains overlapping gene subnetworks for each of the European, East Asian, and Native Hawaiian ancestries when analyzed independently with Hierarchical HotNet<sup>31</sup>. Each node in the network represents a gene. The shading of each node indicates the statistical significance of the association of that gene with triglyceride levels in a particular cohort. Two genes are connected if their protein products interact based on the ReactomeFI 2016<sup>44</sup> (European, East Asian) or iRefIndex 15.0<sup>45</sup> (Native Hawaiian) protein-protein interaction networks. Several genes from the apolipoprotein gene family are significantly associated with triglyceride levels in both the European and East Asian cohorts (see Data Availability). Additionally, the interactions between them form a highly connected subnetwork. Smaller subnetworks identified in the Native Hawaiian cohort are distal modules that are connected to the subnetwork detected in the European cohort. Not all genes in the largest significantly altered subnetwork for the Native Hawaiian ancestry group are shown for visualization purposes (127 not pictured here). Genes that contain SNPs previously associated to triglyceride levels in a European cohort in the GWAS catalog are indicated with <sup>†</sup>. Similarly, genes that contain SNPs previously associated with triglyceride levels in a non-European cohort in the GWAS Catalog are indicated with ‡. The studies identifying these associations are given in Table S16.

#### 453 Supplemental Figures



# Figure S1: Number of publications we identified using UK Biobank data from 2012 to 2020. Studies identified using PMIDs as described in the Supplemental Information. Studies that are displayed on the UK Biobank website (https://www.ukbiobank.ac.uk/) and identified on PubMed are shown in purple. Studies listed on the UK Biobank website but do not have a PMID are shown in blue, and studies only identified using PubMed but not listed on the UK Biobank website are shown in red. The protocols for identifying studies both on PubMed and the UK Biobank website are detailed in the Supplemental Information. Data from both the UK Biobank website and PubMed were accessed on January 12, 2021.

## UK Biobank Studies from 2012 to 2020




Figure S2: Number of studies published using UK Biobank data from 2012 to 2020 that have available metadata in the GWAS Catalog. Our protocols for identifying studies from the GWAS Catalog are detailed in the Supplemental Information. Multi-ancestry studies are shown in purple and include those that list samples of more than one ancestral group in the GWAS catalog (as defined according to the protocol using Popejoy and Fullerton<sup>25</sup>, available on the GitHub page https://github.com/ramachandran-lab/redefining\_replication). Studies that only list samples of European ancestry in the GWAS catalog are shown in blue. Every multi-ancestry analysis includes samples of European ancestry and of at least one other ancestry. GWAS Catalog data was accessed on January 10, 2021 from the website https://www.ebi.ac.uk/gwas/docs/file-downloads using the final release file of 2020 (see file named gwas\_catalog\_v1.0.2-associations\_e100\_r2020-12-15.tsv).




Figure S3: Summaries of replicated associations at multiple genomic scales among ancestry cohorts for all 25 traits analyzed using Bonferroni-corrected thresholds. Expansion of three letter trait codes are given in Table S2. (a) Number and (d) proportion of genome-wide significant SNPs associated with a phenotype in at least one ancestry cohort that were replicated in at least two ancestry cohorts. In all 25 traits, genome-wide significant SNPs replicate in at least two ancestry cohorts. Height contains over 7,000 replicated SNPs among the seven ancestry cohorts analyzed, illustrating its highly polygenic architecture. For many traits across all categories, with the exception of other biochemical (i.e., CRP), the replication rate of genes is higher in gene-level associations than at the SNP-level. (b) Number and (e) proportion of 1Mb windows, or "clumps", that contain at least one genome-wide significant SNP-level associations for a given phenotype in at least two ancestry cohorts. (c) Number and (f) proportion of genome-wide significant gene-level associations that replicate among ancestry cohorts. Replicated associations in hematological are common at the gene-level in hematological and metabolic traits. For instance, in three of the four cohorts with mean corpuscular hemoglobin (MCH) measurements HBA1 and HBA2 were identified as significant associated with MCH in the African, European, and East Asian ancestry cohorts Table S3. The denominator of the proportion is calculated as the total number of unique SNPs, clumps, or genes that are significantly associated with a trait in at least on ancestral cohort. Note that  $\mathbf{d}$  and  $\mathbf{f}$  correspond to Figure 1a and  $\mathbf{b}$ , with an altered x-axis upper limit of 0.8 in this figure.





Figure S4: gene- $\varepsilon$  outperforms and controls false discovery rate (FDR) better than other association methods in simulations with varying heritability and sample size. Simulations were designed to assess gene versus SNP-level association false discovery rate (FDR) and power in an unstructured population as described by the protocols in the Supplemental Information. The top and bottom panels show the FDR and power of four different association methods on 100 simulated datasets, respectively. We compared performance of three gene-level association test methods (gene- $\varepsilon^{38}$ , RSS<sup>60</sup>, SKAT<sup>40</sup>) with outputs from the standard GWA association test under different simulation parameters (sample size N, narrow-sense heritability  $h^2$ , and sparsity). We define sparsity as the proportion of SNPs that are ground-truth causal. Standard errors across the simulated replicates are shown using black whisker plots. Simulation protocol is described in the Supplemental Information.

#### 24



Structured Population

Figure S5: gene- $\varepsilon$  outperforms and controls false discovery rate (FDR) better than other association methods in simulations with varying heritability and sample size. Simulations are designed to assess gene versus SNP-level association false discovery rate (FDR) and power in an structured population as described by the protocols in the Supplemental Information. The top and bottom panels show the FDR and power of four different association methods on 100 simulated datasets, respectively. We compared performance of three gene-level association test methods (gene- $\varepsilon^{38}$ , RSS<sup>60</sup>, SKAT<sup>40</sup>) with outputs from the standard GWA association test under different simulation parameters (sample size N, narrow-sense heritability  $h^2$ , and sparsity). We define sparsity as the proportion of SNPs that are designated to be causal. Standard errors across the simulated replicates are shown using black whisker plots.




Figure S6: gene- $\varepsilon$  identifies associated genes in two simulated ancestry cohorts under a variety of genetic architectures with low narrow sense heritability. a. Precision-recall (top row) and receiver operating curves (bottom row) for gene- $\varepsilon$  analysis of cohorts simulated using genotypes from individuals of European (N = 10,000; blue line) and African (N = 4,967; red line) ancestry, respectively. Narrow-sense heritability was set to  $h^2 = 0.2$  in each simulation. Sparsity of causal SNPs was set to a proportion of 0.1 and the proportion of causal SNPs shared was tested at different values. 50 replicates of each set of simulations under each parameter were performed. b. Precision-recall (top row) and receiver operating curves (bottom row) for gene- $\varepsilon$  analysis of 50 replicated simulations of a European and African cohort using a causal SNP sparsity of 0.5.




Figure S7: gene- $\varepsilon$  identifies associated genes in two simulated ancestry cohorts under a variety of genetic architectures with high narrow sense heritability. a. Precision-recall (top row) and receiver operating curves (bottom row) for gene- $\varepsilon$  analysis of cohorts simulated using genotypes from individuals of European (N = 10,000; blue line) and African (N = 4,967; red line) ancestry, respectively. Narrow-sense heritability was set to  $h^2 = 0.6$  in each simulation. Sparsity of causal SNPs was set to a proportion of 0.1 and the proportion of causal SNPs shared was tested at different values. 50 replicates of each set of simulations under each parameter were performed. b. Precision-recall (top row) and receiver operating curves (bottom row) for gene- $\varepsilon$  analysis of 50 replicated simulations of a European and African cohort using a causal SNP sparsity of 0.5.




Figure S8: gene- $\varepsilon$  (orange) has a lower false discovery rate for identification of shared genetic determinants between cohorts than the standard GWA framework (red). Narrow-sense heritability (percent variance explained by the genotype matrix) was set to  $h^2 = 0.2$  for all simulations. **a.** False discovery rate of shared genetic determinants between two ancestry cohorts using varying levels of causal SNP sparsity and proportion of shared causal SNPs between the cohorts. **b.** Power of gene- $\varepsilon$  and the standard GWA framework to detect shared genetic determinants between two cohorts. Error bars were calculated using the results from 50 simulations of each parameter set of sparsity and proportion of shared causal SNPs for both FDR(a) and Power(b). **c.** Receiver operating curves corresponding to simulations of genetic architecture when causal SNP sparsity is equal to 0.1 (corresponding to the left-hand panels of **a** and **b**). **d.** Receiver operating curves corresponding to the right-hand panels of **a** and **b**).




Figure S9: gene- $\varepsilon$  (orange) has a lower false discovery rate for identification of shared genetic determinants between cohorts than the standard GWA framework (red). Narrow-sense heritability (percent variance explained by the genotype matrix) was set to  $h^2 = 0.6$  for all simulations. **a.** False discovery rate of shared genetic determinants between two ancestry cohorts using varying levels of causal SNP sparsity and proportion of shared causal SNPs between the cohorts. **b.** Power of gene- $\varepsilon$  and the standard GWA framework to detect shared genetic determinants between two cohorts. Error bars were calculated using the results from 50 simulations of each parameter set of sparsity and proportion of shared causal SNPs for both FDR(a) and Power(b). **c.** Receiver operating curves corresponding to simulations of genetic architecture when causal SNP sparsity is equal to 0.1 (corresponding to the left-hand panels of **a** and **b**). **d.** Receiver operating curves corresponding to the right-hand panels of **a** and **b**).




Figure S10: All six ancestries have gene-level associations with platelet count that replicate in at least one other ancestry. Total number of genome-wide significant genes in each ancestry, after correcting for total number of regions tested, are given in the bar plot located in the bottom right (significance thresholds are given in Table S15, sample sizes are given in Table S5 - Table S8). Shared gene-level association statistics between pairs of ancestries are shown in the vertical bar plot; the pair of ancestries represented by each bar can be identified using the dots and links below the barplot. Of the 65 genome-wide significant gene-level association statistics that replicate in at least two ancestry cohorts, only 25 contain SNPs that have been previously associated with platelet count in at least one ancestry in at least one study in the GWAS catalog (https://www.ebi.ac.uk/gwas/home) This plot was generated using the UpSetR package<sup>90</sup>.




Figure S11: Significantly mutated subnetworks associated with triglyceride levels identified in the (a) European, (b) East Asian, and (c) Native Hawaiian ancestry cohorts. Significantly mutated subnetworks were identified using the Hierarchical HotNet method<sup>31</sup>. Genes that were identified in each ancestry as significantly associated with triglyceride levels using the gene- $\varepsilon$  method are shaded using ancestry-specific color coding (also used in Figure 3, European—blue, East Asian—pink, Native Hawaiian green). Significantly mutated subnetworks in the (a) European and (b) East Asian cohorts were identified using the ReactomeFI<sup>44</sup> protein-protein interaction network, and the significantly mutated subnetwork in the (c) the Native Hawaiian cohort was identified using the iRefIndex 15.0<sup>45</sup> protein-protein interaction networks. Genes that are present in any of the significantly mutated subnetworks that contain SNPs previously associated with triglyceride levels in the GWAS Catalog are listed with corresponding citations in Table S16.




Figure S12: Shared SNP-level associations with triglyceride levels in six ancestral cohorts. Total number of genome-wide significant genes in each ancestry, after correcting for total number of regions tested, are given in the bar plot located in the bottom right (significance thresholds are given in Table S10 and sample sizes are given in Table S5 - Table S8). Shared SNP-level association statistics between pairs of ancestries are shown in the vertical bar plot. The pair of ancestries represented by each bar can be identified using the dots and links below the vertical barplot. This plot was generated using the UpSetR package<sup>90</sup>.




Figure S13: Shared gene-level associations with triglyceride levels in five ancestral cohorts. Total number of genome-wide significant genes in each ancestry, after correcting for total number of regions tested, are given in the bar plot located in the bottom right (significance thresholds are given in Table S15 and sample sizes are given in Table S5 - Table S8). Shared gene-level association statistics between pairs of ancestries are shown in the vertical bar plot. The pair of ancestries represented by each bar can be identified using the dots and links below the vertical barplot. This plot was generated using the UpSetR package<sup>90</sup>.




Figure S14: Less stringent significance thresholds lead to a decrease in the proportion of replicated SNP-level associations and an increase in the proportion of gene-level associations among ancestries for each of the 25 traits analyzed. a. Proportion of all SNP-level Bonferronicorrected genome-wide significant associations in any ancestry that replicate in at least one other ancestry is shown on the x-axis (see Table S10 for ancestry-trait specific Bonferroni corrected *p*-value thresholds). On the y-axis we show the proportion of significant gene-level associations that were replicated for a given phenotype in at least two ancestries (see Table S15 for Bonferroni corrected significance thresholds for each ancestry-trait pair). The black stars on the x- and y-axes represent the mean proportion of replicates in SNP and gene analyses, respectively. C-reactive protein (CRP) contains the greatest proportion of replicated SNP-level associations of any of the phenotypes. b. The x-axis indicates the proportion of SNP-level associations that surpass a nominal threshold of p-value  $< 10^{-5}$  in at least one ancestry cohort that replicate in at least one other ancestry cohort. The y-axis indicates the proportion of gene-level associations that surpass a nominal threshold of p-value  $< 10^{-3}$  in at least one ancestry cohort and replicate in at least one other ancestry cohort. Nominal *p*-value thresholds tend to decrease the proportion of replicated SNP-level associations and tend to increase the proportion of replicated gene-level associations. The number of unique SNPs and genes that replicated in each cohort is given in Figure S15. c. The x-axis indicates the proportion of SNP-level associations that surpass a nominal threshold of p-value  $< 10^{-3}$  in at least one ancestry cohort that replicate in at least one other ancestry cohort. The y-axis indicates the proportion of gene-level associations that surpass a nominal threshold of p-value  $< 10^{-2}$  in at least one ancestry cohort and replicate in at least one other ancestry cohort. The number of unique SNPs and genes that replicated in each cohort is given in Figure S16. As shown in panel **b**, nominal *p*-value thresholds tend to decrease the proportion of replicated SNP-level associations and tend to increase the proportion of replicated gene-level associations. Expansion of three letter trait codes are given in Table S2.




Figure S15: Summaries of replicated associations at multiple genomic scales among ancestry cohorts for all 25 traits analyzed using nominal *p*-value thresholds. (a) Number and (c) proportion of genome-wide significant SNPs associated with a phenotype in at least one ancestry cohort that were replicated in at least two ancestry cohorts using a nominal *p*-value threshold of  $5 \times 10^{-5}$ . (b) Number and (d) proportion of genome-wide significant gene-level associations that replicate among ancestry cohorts using a nominal *p*-value threshold of  $10^{-5}$ . (a) Number and (b) proportion of genome-wide significant gene-level associations that replicate among ancestry cohorts using a nominal *p*-value threshold of  $10^{-3}$ . Expansion of three letter trait codes are given in Table S2.




Figure S16: Summaries of replicated associations at multiple genomic scales among ancestry cohorts for all 25 traits analyzed using nominal *p*-value thresholds. (a) Number and (c) proportion of genome-wide significant SNPs associated with a phenotype in at least one ancestry cohort that were replicated in at least two ancestry cohorts using a nominal *p*-value threshold of  $10^{-3}$ . (b) Number and (d) proportion of genome-wide significant gene-level associations that replicate among ancestry cohorts using a nominal *p*-value threshold of  $10^{-3}$ . (b) Number and (d) proportion of genome-wide significant gene-level associations that replicate among ancestry cohorts using a nominal *p*-value threshold of  $10^{-2}$ . Expansion of three letter trait codes are given in Table S2.




Figure S17: Pairwise replication of SNP-level association signals for C-reactive protein in six ancestral cohorts using genotype and imputed data. Imputed data was available and included in this analysis for each of the six cohorts. The inclusion of imputed SNPs in GWA analysis of C-reactive protein increases both the number of significant SNPs in each ancestry (along the diagonal) as well as the number of replicating significant SNP-level associations among pairs of ancestry cohorts (lower triangular). The corresponding analysis of pairwise SNP-level replication using only genotype data from each cohort is shown in Figure 2c.




Figure S18: ADMIXTURE results from self-identified African individuals in the UK Biobank. We performed 10 runs of unsupervised ADMIXTURE<sup>91</sup> setting K = 3 on 4,967 self-identified African individuals in the UK Biobank. We included YRI and CEU individuals from the 1000 Genomes Project<sup>92</sup> to identify European and African ancestry components in the ADMIXTURE results. We then filtered out all individuals with less than 5% membership in the African component (identified as the component shown in green). The AIAN and European ancestry components are shown in blue and red, respectively. Our ADMIXTURE pipeline used the same protocol described in Bitarello and Mathieson<sup>84</sup>. All scripts for ADMIXTURE runs as well as filtration steps are available on the GitHub page given in the Data Availability section.




Figure S19: Multiple prioritized trait clusters with shared core genetic trait architecture replicate in the (a) African (UKB), (b) European, (c) South Asian, and (d) East Asian ancestry cohorts. The WINGS algorithm identified prioritized phenotype clusters in each of these ancestry cohorts, denoted in each dendrogram as clades with emboldened lines. Three clusters of phenotypes were found in all ancestries (shown and labeled in black), comprising: mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH), hemoglobin and hematocrit, and the metabolic traits low-density lipoprotein (LDL) and cholesterol levels. In both the European and East Asian ancestry cohorts, red blood cell count (RBC) was also a member of the hemoglobin and hematocrit phenotype cluster. Two other phenotype clusters were identified in at least two ancestry cohorts. One of these clusters contains white blood cell count (WBC) and neutrophil count, and the other contains diastolic and systolic blood pressure (DBP and SBP). These two clusters are color-coded according to the ancestry cohorts in which they are prioritized. The WINGS algorithm was applied to traits from each ancestry cohort separately as described in the Supplemental Information.

# 454 Supplemental Tables

Ancestry cohort label in this study	$\mathbf{Study}$	Label from original study	Sample Size	Number of SNPs
European	UK Biobank	Self-identified white british	349,411	1,933,096
East Asian	Biobank Japan	East Asian	19,190 - 206,692	4,823,101 - 6,628,005
Hispanic and Latin American	PAGE	Admixed Hispanic and Latin American	15,522 - $21,955$	8,576,622 - 8,822,607
African-American (PAGE)	PAGE	African-American	3,750 - 17,280	12,107,345 - 12,274,127
South Asian	UK Biobank	Self-identified South Asian	5,716	958,375
African (UKB)	UK Biobank	African	4,967	578, 320
Native Hawaiian	PAGE	Native Hawaiian	1,777 - 3,938	6,656,996 - 6,966,169
American Indian/Alaska Native	PAGE	AIAN	574 - 645	3,970,247 - $8,504,923$
Table S1: Ancestry cohor	ts analvzed in this study. In s	Table S1: Ancestry cohorts analyzed in this study. In studies where GWA summary statistics were available to us. sample size and number	re available to us. s	ample size and mumber

of SNPs differ due to original study design. The specific sample size and number of SNPs for each trait in studies from Biobank Japan and PAGE aduition arre and munder ġ. S avallable SULLING 5 W LIGIT LADIE 21: Ancestry conorts analyzed in this study. In studies are provided in Table S4-Table S9.

Trait Name	Code
Body mass index	BMI
High density lipoprotein	HDL
Low density lipoprotein	LDL
Hemoglobin A1c	HBA1C
Estimated glomerular filtration rate	EGFR
C-reactive protein	CRP
Systolic blood pressure	SBP
Diastolic blood pressure	DBP
Platelet count	PLC
Mean corpuscular hemoglobin concentration	MCHC
Mean corpuscular hemoglobin	MCH
Mean corpuscular volume	MCV
Red blood cell count	RBC
White blood cell count	WBC

Table S2: Abbreviations used throughout this study for 14 quantitative traits analyzed in this study. The remaining 11 traits analyzed were Basophil count, Cholesterol, Eosinophil count, Height, Hematocrit, Hemoglobin, Lymphocyte count, Monocyte count, Neutrophil count, and Triglyceride levels, respectively. These are not abbreviated in the main text.

Trait Name or Code	AIAN	Native Hawaiian	Hispanic
BMI	Yes	Yes	Yes
Basophil count	No	No	No
CRP	Yes	Yes	Yes
Cholesterol	Yes	Yes	Yes
DBP	Yes	No	Yes
EGFR	Yes	No	Yes
Eosinophil count	No	No	No
HBA1C	Yes	Yes	Yes
HDL	Yes	Yes	Yes
Height	Yes	Yes	Yes
Hematocrit	No	No	No
Hemoglobin	No	No	No
LDL	Yes	Yes	Yes
Lymphocyte count	No	No	No
MCH	Yes	No	Yes
MCHC	No	No	No
MCV	No	No	No
Monocyte count	No	No	No
Neutrophil count	No	No	No
PLC	Yes	No	Yes
RBC	No	No	No
SBP	Yes	No	Yes
Triglyceride	No	Yes	Yes
Urate	No	No	No
WBC	Yes	No	Yes

Table S3: Traits assayed in the PAGE study data by ancestry cohort. Data were available for each of the 25 listed traits in the UK Biobank European, South Asian, and African cohorts, as well as, the East Asian cohort from the Biobank Japan. Thus, each trait was analyzed in a minimum of four ancestries and a maximum of seven ancestries.

Trait Name or Code	Sample Size	Total SNPs	Pruned SNPs	Regions	Citations
Basophil count	62,076	$5,\!653,\!566$	410,465	$23,\!106$	93
BMI	158,284	$5,\!653,\!566$	410,465	$23,\!085$	94
CRP	75,391	5,608,701	408,166	23,108	93
DBP	136,615	5,653,566	410,465	23,085	93
eGFR	143,658	5,608,701	408,166	23,108	93
Eosinophil count	62,076	5,653,566	410,465	23,106	93
HDL	70,657	5,608,701	408,166	23,108	93
Height	159,095	6,296,332	354,647	23,679	95
Hematocrit	108,757	5,653,566	410,465	23,106	93
Hemoglobin	108,769	5,653,566	410,465	23,085	93
HbA1c	75,391	5,608,701	408,166	23,108	93
LDL	72,866	5,608,701	408,166	23,108	93
Lymphocyte count	62,076	$5,\!653,\!566$	410,465	23,106	93
MCH	108,054	5,653,566	410,465	23,106	93
MCHC	108,738	5,653,566	410,465	23,106	93
MCV	108,526	5,653,566	410,465	23,085	93
Monocyte count	62,076	5,653,566	410,465	23,106	93
Neutrophil count	62,076	5,653,566	410,465	23,106	93
PLC	108,208	5,653,566	410,465	23,085	93
RBC	108,794	$5,\!653,\!566$	410,465	23,085	93
SBP	136,597	$5,\!653,\!566$	410,465	23,085	93
Cholesterol	128,305	5,608,701	408,166	23,108	93
Triglyceride	105,597	5,608,701	410,465	23,108	93
Urate	109,029	5,608,701	408,166	23,108	93
WBC	107,694	$5,\!653,\!566$	408,166	23,085	93

Table S4: Number of individuals, total SNPs, pruned SNPs used for gene- $\varepsilon$ , and genes and transcription factors (regions) included in the analysis for each trait in Biobank Japan data. Regions were defined using the hg19 list provided in Gusev et al.<sup>42</sup>.

Trait Name or Code	Sample Size	Total SNPs	Pruned SNPs	Regions
BMI	17,127	$12,\!139,\!115$	404,401	24,216
CRP	8,349	12,274,126	$404,\!572$	24,206
DBP	11,380	12,148,801	405,188	24,218
eGFR	8,261	12,128,273	403,371	24,207
Hemoglobin A1c	17,127	12,139,115	404,401	24,215
HDL	10,085	12,114,827	404,089	24,201
Height	17,280	$12,\!139,\!907$	404,522	24,201
LDL	9,720	12,107,344	403,740	24,218
MCHC	3,750	12,132,232	405,558	24,217
PLC	8,850	$12,\!131,\!935$	404,497	24,193
SBP	11,380	12,148,801	405,188	24,218
Cholesterol	10,137	12,110,337	403,674	24,222
Triglyceride	9,980	12,110,879	$403,\!455$	24,206
WBC	8,802	12,126,732	404,579	24,219

Table S5: Number of individuals, total SNPs, pruned SNPs used for gene- $\varepsilon$ , and genes and transcription factors (regions) included in the analysis for each trait in the African-American cohort of the PAGE study data.

Trait Name or Code	Sample Size	Total SNPs	Pruned SNPs	Region Count
BMI	21,955	8,812,436	432,762	24,138
CRP	15,912	8,576,621	397,941	24,118
DBP	21,549	8,784,112	430,360	24,126
Estimated glomerular filtration rate	18,548	8,702,426	422,598	24,123
HbA1c	21,955	8,812,436	432,762	24,138
HDL	17,751	$8,\!583,\!603$	412,771	24,122
Height	22,187	8,822,606	433,604	24,132
LDL	17,373	8,588,800	413,074	24,116
MCHC	15,522	8,763,739	427,208	24,132
PLC	18,949	8,612,804	415,201	24,115
SBP	21,549	8,784,112	430,360	24,126
Cholesterol	17,802	8,586,887	412,830	24,115
Triglyceride	17,856	8,594,121	413,546	24,104
WBC	18,206	8,603,503	414,462	24,123

Table S6: Number of individuals, total SNPs, pruned SNPs used for gene- $\varepsilon$ , and genes and transcription factors (regions) included in the analysis for each trait in the Hispanic and Latin American cohort of the PAGE study data.

Trait Name or Code	Sample Size	Total SNPs	Pruned SNPs	Regions
BMI	645	8,374,976	421,826	24,124
CRP	574	8,504,922	417,287	24,136
DBP	636	$8,\!376,\!521$	421,528	$24,\!136$
eGFR	602	8,336,044	417,540	24,132
Hemoglobin A1c	645	8,374,976	421,826	24,124
HDL	604	8,315,912	415,939	24,121
Height	645	$8,\!375,\!624$	421,750	24,117
LDL	591	8,360,719	419,544	24,123
MCHC	20	$3,\!970,\!246$	62,339	17,381
PLC	603	8,294,302	414,530	24,133
Systolic blood pressure	636	8,376,521	421,528	24,136
Cholesterol	604	$8,\!586,\!887$	415,939	24,121
WBC	602	$8,\!289,\!567$	414,462	$24,\!133$

Table S7: Number of individuals, total SNPs, pruned SNPs used for gene- $\varepsilon$ , and genes and transcription factors (regions) included in the analysis for each trait in the AIAN cohort of the PAGE study data.

Trait Name or Code	Sample Size	Total SNPs	Pruned SNPs	Regions
BMI	3,936	$6,\!664,\!738$	415,221	$23,\!885$
$\operatorname{CRP}$	1,777	6,966,169	428,517	$23,\!834$
Hemoglobin A1c	3,936	$6,\!664,\!738$	415,221	$23,\!885$
HDL	1,912	$6,\!656,\!996$	416,255	$23,\!894$
Height	3,938	$6,\!660,\!920$	415,172	$23,\!878$
LDL	1,900	$6,\!662,\!802$	416,810	$23,\!895$
Cholesterol	1,915	6,660,807	416,425	23,899
Triglycerides	1,915	$6,\!660,\!807$	416,425	$23,\!899$

Table S8: Number of individuals, total SNPs, pruned SNPs used for gene- $\varepsilon$ , and genes and transcription factors (regions) included in the analysis for each trait in the Native Hawaiian (Native Hawaiian) cohort of the PAGE study data.

Trait Name or Code	Sample Size	Total SNPs	Pruned SNPs	Regions
BMI	4,647	$15,\!362,\!633$	433,356	24,085
CRP	1,811	$14,\!374,\!461$	428,656	24,116
DBP	1,086	$12,\!470,\!507$	416,273	24,112
eGFR	150	8,314,417	$337,\!167$	24,017
HbA1c	4,647	$15,\!362,\!633$	433,356	24,085
HDL	$2,\!378$	13,413,244	428,598	24,072
Height	4,679	$15,\!366,\!710$	433,005	24,103
LDL	2,316	13,327,313	428,741	24,075
MCHC	128	$8,\!089,\!136$	$315{,}583$	23,946
PLC	541	$10,\!528,\!072$	421,929	24,098
SBP	1,086	$12,\!470,\!507$	416,273	24,112
Cholesterol	$2,\!387$	$13,\!436,\!190$	428,656	24,078
Triglyceride	2,381	$13,\!423,\!953$	429,246	24,073
WBC	543	$10,\!570,\!051$	421,776	24,095

Table S9: Number of individuals, total SNPs, pruned SNPs used for gene- $\varepsilon$ , and genes and transcription factors (regions) included in the analysis for each trait in the Asian cohort of the PAGE study data.

Trait Name or Code	African or African-American	East Asian	AIAN	Native Hawaiian	Hispanic
	$(\times 10^{-8})$	$(\times 10^{-8})$	$(\times 10^{-8})$	$(\times 10^{-9})$	$(\times 10^{-8})$
Basophil count	$8.646^{*}$	8.844	NA	NA	NA
BMI	0.412	8.844	0.597	7.502	5.674
CRP	0.407	8.915	0.588	7.176	5.830
Cholesterol	0.414	8.915	0.601	7.507	5.823
DBP	0.412	8.844	0.597	NA	5.692
EGFR	0.412	8.915	0.600	NA	5.746
Eosinophil count	$8.646^{*}$	8.844	NA	NA	NA
HBA1C	0.412	8.915	0.597	7.502	5.674
HDL	0.413	8.915	0.601	7.511	5.825
Height	0.412	7.941	0.597	7.506	5.667
Hematocrit	$8.646^{*}$	8.844	NA	NA	NA
Hemoglobin	8.646*	8.844	NA	NA	NA
LDL	0.413	8.914	0.598	7.504	5.822
Lymphocyte count	$8.646^{*}$	8.843	NA	NA	NA
MCH	$8.646^{*}$	8.844	NA	NA	NA
MCHC	0.412	8.844	1.259	NA	5.705
MCV	$8.646^{*}$	8.844	NA	NA	NA
Monocyte count	$8.646^{*}$	8.844	NA	NA	NA
Neutrophil count	$8.646^{*}$	8.844	NA	NA	NA
PLC	0.412	8.844	0.603	NA	5.805
RBC	$8.646^{*}$	8.844	NA	NA	NA
SBP	0.412	8.844	0.597	NA	5.692
Triglyceride	0.413	8.915	NA	7.507	5.818
Urate	$8.646^{*}$	8.915	NA	NA	NA
WBC	0.412	8.844	NA	NA	5.812

pair. Thresholds are calculated as 0.05 divided by the number of SNPs tested in each ancestry-trait pair. The term "NA" indicates that there was no data for that ancestry-trait pair. The threshold for Bonferroni-corrected significance was the same for every trait in the European (*p*-value Table S10: Bonferonni *p*-value threshold corrected for number of SNP-level association tests performed for each ancestry-trait  $< 2.587 \times 10^{-8}$ ) and South Asian (*p*-value  $< 5.217 \times 10^{-8}$ ) cohorts from the UK Biobank. Traits for which the UK Biobank African cohort was used are denoted with a \*; otherwise, the African-American cohort from the PAGE study data was used. See Table S2 for expansion of trait codes.

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.20.440612; this version posted November 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Trait Name or Code	Median Effect Size Correlation	$\begin{array}{ c c } \hline {\rm Effect~Sizes} \\ > 0.1~({\rm Mean}) \end{array}$	Median PIP Correlation	$egin{array}{c} { m PIPs} > 0.01 \ { m (Mean)} \end{array}$
BMI	0.0143	0	0.073	67.3
Basophil	$3.69 \times 10^{-6}$	0	0.002	211.8
CRP	0.096	0.7	0.159	142.6
Cholesterol	0.966	1	0.232	53.1
DBP	0.001	0.6	0.012	173.1
EGFR	$4.71 \times 10^{-6}$	0	0.005	149
Eosinophil	0.0179	0.2	0.042	325.8
HBA1C	0.012	0.2	0.025	26.8
HDL	0.325	0.1	0.219	57.6
Height	$9.20 \times 10^{-5}$	1.6	0.010	187.7
Hematocrit	$-4.16 \times 10^{-6}$	0.5	0.015	40.3
Hemoglobin	$-1.13 \times 10^{-5}$	0.6	0.014	45.8
LDL	0.949	1	0.331	60.9
Lymphocyte	$-1.01 \times 10^{-6}$	1.5	0.001	1368.5
MCH	$7.098 \times 10^{-6}$	0.6	0.007	60.9
MCHC	$-2.00 \times 10^{-6}$	0.9	0.01	58.7
MCV	$1.71 \times 10^{-5}$	0.6	0.01	70
Monocyte	0.002	0.1	0.017	349.4
Neutrophil	0.038	0.1	0.071	66.5
PLC	0.609	0.9	0.154	112.5
RBC	$9.650 \times 10^{-5}$	0.9	0.028	49.7
SBP	0.001	0.6	0.019	166.8
Triglyceride	0.348	0.0	0.247	164.7
Urate	0.252	0.5	0.24	39.9
WBC	0.0002	0.1	0.01	347.8

Table S11: Replication of effect sizes and posterior inclusion probabilities (PIPs) among ten independent subsamples of the UK Biobank European ancestry cohort using SuSiE<sup>34</sup> for finemapping. The sample size of the ten independent, non-overlapping subsamples of the UK Biobank European ancestry cohort was set to 10,000. For the 1,895,051 SNPs that were analyzed in every European ancestry cohort subsample (Table S1) and the effect sizes and PIPs (columns 2 and 4, respectively) generated using the SuSiE method<sup>34</sup>, we calculated the median correlation coefficient between all possible pairwise comparisons (10 choose 2) of the European ancestry cohort subsamples. Column 3 reports the mean number of SNPs with effect sizes greater than 0.1 across all ten European ancestry cohort subsamples for each trait. Column 5 reports the mean number of SNPs with a posterior inclusion probability greater than 0.01 across the ten European ancestry cohort subsamples for each trait.

European PIPs > 0.01 (Mean)	8.9	40.3	33.6	8.4	20.3	24.7	29.3	6.5	11.6	ava 23.7	labl	12.5 <sup>e</sup>	13.5 der	115.5 a	-BA	13.6 Z	11.8 Z	27.7 5	10.2	rnat 13.7	12.7 oi	20	25.6	9.8	48.3	
Euro > 0.0																										
$\begin{array}{l} {\rm African}\\ {\rm PIPs} > 0.01 \end{array}$	1206	403	95	1144	1249	984	626	959	31	208	199	568	995	60	1332	646	917	2215	2386	2088	3	1133	2231	334	2862	
Median PIP Correlation	0.027	0.001	$5.88  imes 10^{-5}$	0.467	0.008	0.001	0.003	0.004	0.014	0.003	0.016	0.022	0.497	0.001	0.005	0.008	0.005	0.002	0.001	0.035	-0.002	0.008	0.009	0.051	0.0006	
Number of Shared PIPs > 0.01	1	0	0	5	0	0	0	0	2	0	0	0	×	1	0	0	0	2	0	3	0	0	8	3	5	
European Effect Sizes > 0.1 (Mean)	0	0	0.4	0.9	0.3	0	0	0.2	0.1	0.7	0	0	1	0	0.2	0.2	0.2	0	0	0.0	0.1	0.1	0.1	0.3	0	
African Effect Sizes > 0.1	2	0	0	1	10	7	0	5	0	19	1	1	1	0	1	1	1	0	1	1	1	13	0	2	1	
Median Effect Size Correlation	$5.12  imes 10^{-5}$	$-3.01 \times 10^{-5}$	$-3.68 \times 10^{-6}$	0.5	$1.58 \times 10^{-5}$	$2.41 \times 10^{-6}$	$-1.97 \times 10^{-5}$	$-1.15 \times 10^{-6}$	0.014	$-1.22 \times 10^{-5}$	$-1.14 \times 10^{-5}$	$-6.31 \times 10^{-6}$	0.674	$2.71 \times 10^{-5}$	$1.14 \times 10^{-5}$	$-1.56 \times 10^{-6}$	$2.58 \times 10^{-6}$	$-2.44 \times 10^{-5}$	-0.0001	-0.017	$-6.35 \times 10^{-6}$	$4.31\! imes\!10^{-5}$	0.004	0.01	-0.0001	
Number of Shared Effect Sizes > 0.1	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	
Trait Name or Code	BMI	Basophil	CRP	Cholesterol	DBP	EGFR	Eosinophil	HBA1C	HDL	Height	Hematocrit	Hemoglobin	LDL	${ m Lymphocyte}$	MCH	MCHC	MCV	Monocyte	Neutrophil	PLC	RBC	$\operatorname{SBP}$	Triglyceride	Urate	WBC	

cohort and ten independent subsamples of the UK Biobank European ancestry cohort using SuSiE<sup>34</sup> for fine-mapping. Each of threshold of 0.01. Column 2 reports the number of SNPs that surpassed an effect size of 0.1 in both the African ancestry cohort and at least one of the ten independent, non-overlapping subsamples of the UK Biobank European ancestry cohort was set to be equal in size to the sample size of the of effect sizes greater than 0.1 in the European ancestry cohort subsamples for each trait. We performed the same comparison for the PIPs using a Table S12: Replication of effect sizes and posterior inclusion probabilities (PIPs) between the UK Biobank African ancestry African ancestry cohort (N = 4,967), Table S1. Column headers containing "(mean)" indicate a mean is generated averaging over the ten independent European ancestry cohort subsamples. For the 496,997 SNPs that were analyzed in both the African ancestry cohort and every European ancestry cohort subsample, we compared the  $SuSiE^{34}$  effect size estimates and PIPs. For both effect sizes and PIPs, the median correlation coefficient between the African ancestry cohort and the pairwise comparison to each European ancestry cohort subsample is reported in the third and seventh columns, respectively. Column 3 reports the total number of SNPs with effect sizes greater than 0.1 in the African cohort. Column four gives the mean number the European ancestry cohort subsamples. Column 6 reports the number of SNPs that surpasses a PIP of 0.01 in the African ancestry cohort and at least one European ancestry cohort subsample.

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.20.440612; this version posted November 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NO-ND 4.0 International license.

50

un)	1 1 1 1 0	10 11				y he		101	10) 15	ava	ilabl	e un	der	a <mark>CC</mark>	-BY	-NC	-ND	4.0	Inte	rnat	iona		ense		ay l	ne pre
European PIPs > 0.01 (Mean)	18	78.4	64.7	6	40	44.2	69.1	13.3	12.2	66.8	17.4	16.1	15.6	343.1	22.3	20.3	26.3	76.8	25.7	22.7	20.9	43.2	46.4	15.8	93	ncestry
South Asian PIPs > 0.01	180	210	181	20	115	452	63	133	78	754	24	19	44	113	78	45	81	156	70	126	41	116	189	52	52	k South Asian a
Median PIP Correlation	0.0173	0.0008	0.121	0.0127	0.013	$5.12{ imes}10^{-5}$	0.006	0.011	0.505	0.001	$6.24 \times 10^{-5}$	0.011	0.386	0.0001	0.008	0.007	0.005	0.001	0.172	0.679	-0.011	0.037	0.173	0.150	0.008	the UK Bioban
Number of Shared PIPs > 0.01	0	0	17	2	0	0	0	0	ç	1	0	0	14	0	0	0	0	0	16	1	0	0	53	9	18	Table S13: Replication of effect sizes and posterior inclusion probabilities (PIPs) between the UK Biobank South Asian ancestry
$\begin{array}{c} {\rm European} \\ {\rm Effect Sizes} \\ > 0.1 \\ ({\rm Mean}) \end{array}$	0	0	0.4	0.0	0.6	0	0	0.3	0.1	1.1	0.3	0.3	1	1.1	0.5	0.9	0.5	0.1	0	0.8	0.3	0.3	0	0.4	0	ion probabilities
South Asian Effect Sizes > 0.1	1	0	0	0	0	0	0	2	0	12	1	1	1	0	2	1	3	0	0	0	0	0	0	1	0	posterior inclusi
Median Effect Size Correlation	$7.07 \times 10^{-5}$	$-1.10 \times 10^{-5}$	0.0309	0.004	$-2.12 \times 10^{-5}$	$-1.26 \times 10^{-5}$	$2.16{ imes}10^{-5}$	$-3.33 \times 10^{-5}$	0.525	$-2.13 \times 10^{-5}$	$-4.78 \times 10^{-6}$	$-4.19 \times 10^{-6}$	0.491	$-4.40 \times 10^{-6}$	$5.29 \times 10^{-6}$	$-5.77 \times 10^{-6}$	$1.74 \times 10^{-5}$	-4.05 $\times 10^{-6}$	0.221	0.577	$2.79 \times 10^{-6}$	-0.0004	0.158	0.137	0.001	effect sizes and
Number of Shared Effect Sizes > 0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	: Replication of
Trait Name or Code	BMI	Basophil	CRP	Cholesterol	DBP	EGFR	Eosinophil	HBA1C	HDL	Height	Hematocrit	Hemoglobin	TDL	Lymphocyte	MCH	MCHC	MCV	Monocyte	Neutrophil	PLC	RBC	$\operatorname{SBP}$	Triglyceride	Urate	WBC	Table S13.

51

cohort and ten independent subsamples of the UK Biobank European ancestry cohort using SuSiE<sup>34</sup> for fine-mapping. Each of Asian ancestry cohort and at least one of the European ancestry cohort subsamples. Column 6 reports the number of SNPs that surpasses a PIP of the ten independent, non-overlapping subsamples of the UK Biobank European ancestry cohort was set to be equal in size to the sample size of the South Asian ancestry cohort (N = 5,660), Table S1. Column headers containing "(mean)" indicate a mean is generated averaging over the ten independent European ancestry cohort subsamples. For the 863,569 SNPs that were analyzed in both the South Asian ancestry cohort and every coefficient between the South Asian ancestry cohort and the pairwise comparison to each European ancestry cohort subsample is reported in the Column four gives the mean number of effect sizes greater than 0.1 in the European ancestry cohort subsamples for each trait. We performed the European ancestry cohort subsample, we compared the  $SuSiE^{34}$  effect size estimates and PIPs. For both effect sizes and PIPs, the median correlation third and seventh columns, respectively. Column 3 reports the total number of SNPs with effect sizes greater than 0.1 in the South Asian cohort. same comparison for the PIPs using a threshold of 0.01. Column 2 reports the number of SNPs that surpassed an effect size of 0.1 in both the South 0.01 in the South Asian ancestry cohort and at least one European ancestry cohort subsample.

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.20.440612; this version posted November 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NO-ND 4.0 International license.

PESCA both and GWA nominal significance in both	94	11	27	13	39	44	15
PESCA both and EAS GWA nominal significance	539	54	74	43	180	215	49
PESCA both and EUR GWA nominal significance	97	14	29	16	39	44	15
PESCA EAS only and EAS GWA nominal significance	0	13	8	6	14	11	8
PESCA EUR only and EUR GWA nominal significance	0	2	5	0	3		4
Trait	BMI	Cholesterol	HDL	TDL	MCH	MCV	Triglyceride

and the East Asian ancestry cohort from the Biobank Japan. For seven continuous traits, we compared SNP-level association *p*-values from our analysis to the posterior probabilities calculated in Shi et al. <sup>51</sup> using the PESCA framework. For each of the seven traits, there were SNPs that Table S14: Overlap between SNPs identified by PESCA and GWA analyses in the European ancestry cohort from the UK Biobank had a posterior probability > 0.8 of being causal in both ancestries and were also nominally significant (*p*-value  $5 < 10^{-6}$ ) using the standard GWA SNP-level framework.

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.20.440612; this version posted November 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

NNative HawaiianHispanic and Latin American6) $(\times 10^{-6})$ $(\times 10^{-6})$	NA	2.093 2.072		2.092 2.073	NA 2.073	NA	NA NA	2.093 2.072	2.093 2.073	2.094 2.072	NA NA	NA NA	2.093 2.073	NA NA	NA NA		NA NA	NA NA	NA NA	NA 2.073	NA NA	NA 5.692	2.072 2.073	NA NA	
$  AIAN (\times 10^{-6})$	NA	2.073	2.072	2.073	2.072	2.073	NA	2.073	2.073	2.073	NA	NA	2.073	NA	NA	2.877	NA	NA	NA	2.072	NA	0.597	NA	NA	
East Asian $(\times 10^{-6})$	2.197	2.197	2.085	2.198	2.197	2.198	2.197	2.198	2.198	2.131	2.197	2.197	2.198	2.197	2.197	2.197	2.197	2.197	2.197	2.197	2.197	8.844	2.197	2.197	
African or African-American $(\times 10^{-6})$	1.121	2.096	2.097	2.096	2.096	2.097	$2.121^{*}$	2.096	2.097	2.097	$2.121^{*}$	$2.121^{*}$	2.096	$2.121^{*}$	$2.121^{*}$	2.096	$2.121^{*}$	$2.121^{*}$	$2.121^{*}$	2.097	$2.121^{*}$	0.412	2.096	$2.121^{*}$	
Trait	Basophil count	BMI	CRP	Cholesterol	DBP	EGFR	Eosinophil count	HBA1C	HDL	Height	Hematocrit	Hemoglobin	TDL	Lymphocyte count	MCH	MCHC	MCV	Monocyte count	Neutrophil count	PLC	RBC	SBP	Triglyceride	Urate	

pair. Thresholds are calculated as 0.05 divided by the number of SNPs tested in each ancestry-trait pair. The term "NA" indicates that there was no data for that ancestry-trait pair. The threshold for Bonferroni-corrected significance was the same for every trait in the European (*p*-value Table S15: Bonferonni *p*-value threshold corrected for number of gene-level association tests performed for each ancestry-trait  $< 2.092 \times 10^{-6}$ ) and South Asian (*p*-value  $< 1.085 \times 10^{-6}$ ) cohorts from the UK Biobank. Traits for which the UK Biobank African cohort was used are denoted with a \*; otherwise, the African-American cohort from the PAGE study data was used. See Table S2 for expansion of trait codes.

Gene	African or African-American	European	East Asian	Hispanic
ANGPTL4	96	97	NA	97
APOA1	98	98	NA	98
APOA4	NA	99	NA	NA
APOA5	100	100-103	104	100
APOB	105	105	NA	105
APOC1	98	99	NA	98
APOC2	100	100	NA	100
APOC3	98	98,99	NA	98
APOC4	99	99	NA	99
APOE	99	99,100	NA	99
CETP	98	99	NA	98
LMF1	NA	99	NA	NA
LPL	98	99	104	98
PCSK6	96	99	NA	96
PCSK7	100	100	104	100
PLTP	97,98,100,105	97 - 99,105 - 107	NA	97,98,100,105

Table S16: Genes shown in Figure 3 as associated with triglyceride levels are supported by publications in the GWAS Catalog. Each of the genes listed is present in the significantly mutated subnetworks identified using Hierarchical HotNet<sup>31</sup> as enriched for associations with triglyceride levels in the European, East Asian, or Native Hawaiian ancestry cohorts. We mapped SNP-level associations from the GWAS Catalog to the 29 genes present in the significantly mutated subnetworks shown in Figure 3 (using the gene list provided by Gusev et al.<sup>42</sup>) to generate the results for the 16 genes shown here.

Gene	African-American	European	South Asian	East Asian	AIAN	Hispanic and Latin American
RDH13	$4.14 \times 10^{-10}$	$9.95  imes 10^{-1}$	$8.80\times10^{-2}$	$1.76\times10^{-6}$	1	$7.88 \times 10^{-1}$
AGPAT5	1	$1.30 \times 10^{-6}$	$7.83 \times 10^{-1}$	$5.00 \times 10^{-1}$	$7.33\times10^{-8}$	1
GP6	$7.20 \times 10^{-10}$	$9.93  imes 10^{-1}$	$1.47  imes 10^{-1}$	$9.07  imes 10^{-7}$	1	$6.92  imes 10^{-1}$
ALDH2	1	$1.00\times10^{-20}$	$1.13\times 10^{-2}$	$1.00\times10^{-20}$	1	1
RAB8A	$9.57 \times 10^{-1}$	$1.00 \times 10^{-20}$	1	$5.76\times10^{-6}$	1	$9.97 \times 10^{-1}$
CUX2	1	$5.13 \times 10^{-7}$	$1.16 \times 10^{-1}$	$3.44\times10^{-11}$	1	1
ACAD10	1	$1.47\times 10^{-10}$	$1.10\times 10^{-2}$	$2.00\times10^{-10}$	1	1

Table S17: Gene-level association *p*-values for seven genes associated with platelet count in at last two ancestry cohorts. Of the 65 genes that were associated with platelet count in at least two ancestry cohorts, these seven contained previously identified SNP-level associations in studies submitted to the GWAS Catalog. Previous associations in the GWAS Catalog are discussed in the Supplemental Information. Ancestry-specific Bonferroni corrected significance thresholds for gene-level association analysis of platelet count are shown in Table S15.

Gene	African-American (PAGE)	European	South Asian	East Asian	Native Hawaiian	Hispanic and Latin American
APOA1	$4.99 \times 10^{-1}$	$1.00 \times 10^{-20}$	$9.91 \times 10^{-1}$	$1.00 \times 10^{-20}$	$7.52\times10^{-1}$	$4.99\times10^{-1}$
APOA4	$4.99\times 10^{-1}$	$1.00 \times 10^{-20}$	$2.51\times 10^{-5}$	$1.00 \times 10^{-20}$	$9.15 \times 10^{-1}$	$4.99\times10^{-1}$
APOA5	$4.99\times 10^{-1}$	$1.42 \times 10^{-11}$	$1.60\times 10^{-6}$	$9.95  imes 10^{-1}$	$3.67\times10^{-12}$	$4.99\times 10^{-1}$
APOC3	$4.99\times 10^{-1}$	$1.00 \times 10^{-20}$	$9.82 \times 10^{-1}$	$9.83 \times 10^{-1}$	$3.05\times10^{-15}$	$4.99\times 10^{-1}$
APOE	$4.99\times 10^{-1}$	$1.00 \times 10^{-20}$	$8.65\times10^{-1}$	$1.00 \times 10^{-20}$	1	1
PLTP	$4.99\times 10^{-1}$	$4.29 \times 10^{-9}$	$9.66 \times 10^{-1}$	$6.66 \times 10^{-15}$	$1.00\times 10^{-2}$	$4.99\times 10^{-1}$
LPL	$4.99\times 10^{-1}$	$4.08 \times 10^{-13}$	$3.00 \times 10^{-3}$	$1.00\times10^{-20}$	$6.59\times 10^{-1}$	$4.99\times 10^{-1}$
ANGPTL3	$4.99\times 10^{-1}$	$8.86 \times 10^{-8}$	$2.00 \times 10^{-3}$	$1.00 \times 10^{-20}$	$4.00 \times 10^{-3}$	1
ANGPTL4	$4.99\times 10^{-1}$	$1.00 \times 10^{-20}$	$9.78 \times 10^{-1}$	$9.99 \times 10^{-1}$	$9.89  imes 10^{-1}$	1
APOC1	$4.99\times 10^{-1}$	$1.67 \times 10^{-16}$	$4.99\times10^{-1}$	$1.00 \times 10^{-20}$	$9.81\times10^{-1}$	$4.99\times10^{-1}$
APOC2	$4.99\times 10^{-1}$	$3.57 \times 10^{-13}$	$7.71  imes 10^{-1}$	$1.11 \times 10^{-1}$	$9.11  imes 10^{-1}$	$4.99\times 10^{-1}$
APOC4	$4.99\times 10^{-1}$	$3.72 \times 10^{-13}$	$7.36  imes 10^{-1}$	$2.58\times10^{-14}$	$9.73\times10^{-1}$	$4.99\times 10^{-1}$
APOB	$4.99\times 10^{-1}$	$1.00 \times 10^{-20}$	$9.99 \times 10^{-1}$	$7.32 \times 10^{-12}$	$1.00 \times 10^{-3}$	1
LMF1	$9.98  imes 10^{-1}$	$8.03 \times 10^{-7}$	1	$3.21\times 10^{-2}$	$3.79  imes 10^{-5}$	$9.98\times 10^{-1}$
APOL1	$4.99\times 10^{-1}$	$5.30 \times 10^{-2}$	$6.40\times 10^{-2}$	1	$8.89\times10^{-11}$	$4.99\times 10^{-1}$
HBA1	$4.99\times 10^{-1}$	$3.75\times10^{-5}$	$9.99  imes 10^{-1}$	$4.51\times10^{-1}$	$2.46\times10^{-10}$	1
HBA2	$4.99\times 10^{-1}$	$1.30 \times 10^{-5}$	$9.99  imes 10^{-1}$	$4.51 \times 10^{-1}$	$3.93\times10^{-10}$	$4.99\times10^{-1}$
B4GALT3	$4.99  imes 10^{-1}$	$6.80\times10^{-2}$	$7.21  imes 10^{-1}$	$4.99  imes 10^{-1}$	$1.23\times 10^{-6}$	1
KLK8	1	1	$1.62\times 10^{-6}$	$9.89  imes 10^{-1}$	$1.00  imes 10^{-3}$	1
PNLIP	$4.99\times 10^{-1}$	$9.99 \times 10^{-1}$	$9.26  imes 10^{-1}$	$7.75 \times 10^{-1}$	$1.00 \times 10^{-3}$	$4.99\times 10^{-1}$
WNT4	$4.99\times 10^{-1}$	$9.61\times10^{-1}$	$9.99  imes 10^{-1}$	$4.99 \times 10^{-1}$	$3.29\times 10^{-5}$	$4.99\times 10^{-1}$
BACE1	$4.99\times 10^{-1}$	$5.55 \times 10^{-17}$	$2.20\times 10^{-2}$	$9.99\times10^{-16}$	$6.69  imes 10^{-1}$	$4.99\times 10^{-1}$
CETP	$4.99\times 10^{-1}$	$1.00 \times 10^{-3}$	$9.99  imes 10^{-1}$	$1.41\times 10^{-6}$	$9.99  imes 10^{-1}$	$4.99\times 10^{-1}$
PCSK6	$4.99\times 10^{-1}$	1	$9.99 \times 10^{-1}$	$1.83 \times 10^{-5}$	$1.00 \times 10^{-3}$	$4.99\times10^{-1}$
PCSK7	$4.99\times 10^{-1}$	$1.66 \times 10^{-8}$	$9.97  imes 10^{-1}$	$1.00 \times 10^{-20}$	$9.99  imes 10^{-1}$	$4.99\times10^{-1}$
LCAT	$4.99\times 10^{-1}$	$5.00 \times 10^{-1}$	1	$6.24\times10^{-3}$	$4.38\times10^{-1}$	$4.99\times 10^{-1}$
APOF	$4.99\times 10^{-1}$	$5.78 \times 10^{-1}$	$7.79  imes 10^{-1}$	$4.10\times10^{-3}$	$9.64\times10^{-1}$	$4.99\times 10^{-1}$
TYRO3	$4.99\times 10^{-1}$	$9.28 \times 10^{-1}$	$9.99  imes 10^{-1}$	$1.20\times10^{-2}$	$8.57\times10^{-1}$	$4.99\times10^{-1}$

Table S18: Gene- $\varepsilon$  *p*-values for the 28 genes present in the significantly mutated sunnetworks associated with triglyceride level in the European, East Asian, and Native Hawaiian cohorts. Each of these genes is present in Figure 3 which depicts the overlapping significantly mutated subnetworks identified using Hierarchical HoNet<sup>31</sup> identified in an analysis of triglyceride levels in the European, East Asian, and Native Hawaiian cohorts. Known SNP-level associations identified within the bounds of these genes in previous studies submitted to the GWAS Catalog are discussed in the Supplemental Information. Ancestry-specific Bonferroni corrected significance thresholds for gene-level association analysis of triglyceride levels are shown in Table S15.

# 455 S1 Supplemental Information

# 456 Supplemental Subjects and Methods

## 457 UK Biobank Data

We downloaded individual genotype data using the UK Biobank's (UKB) ukbgene resource, https:// biobank.ctsu.ox.ac.uk/crystal/download.cgi. European individuals from the UK Biobank data were selected using the self-identified ancestry (data field 21000) using values outlined at https://biobank. ctsu.ox.ac.uk/crystal/field.cgi?id=21000. Using the relatedness file provided by the UK Biobank, one individual from each related pair was then randomly removed. This process was repeated for individuals whose self-identified ancestry was South Asian.

We performed unsupervised genome-wide ancestry estimation using ADMIXTURE by setting  $K = 3^{91}$  on 464 the self-identified African ancestry cohort. We also included YRI and CEU individuals in the ADMIXTURE 465 runs from the 1000 Genomes Project, to identify the ancestry components corresponding to African and Euro-466 pean ancestry. We removed individuals containing less than 5% membership in the African ancestry compo-467 nent and more than 5% membership in the third component, which corresponds to American Indian/Alaskan 468 Native (AIAN) ancestry (Figure S18). We downloaded imputed SNP data from the UK Biobank for all re-469 maining individuals and removed SNPs with an information score below 0.8. Information scores for each SNP 470 are provided by the UK Biobank (http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=1967). The 471 remaining genotype and high-quality imputed SNPs were put through a stringent quality control pipeline in 472 each ancestry cohort to obtain cohort-specific SNPs to be used for further analysis as detailed in the main 473 text (detailed below). 474

We performed the following quality control filters in the European, South Asian, and African cohorts 475 from the UK Biobank (Application number 22419). Genotype data for 488,377 individuals in the UK 476 Biobank were downloaded using the UK Biobank's ukbgene (https://biobank.ctsu.ox.ac.uk/crystal/ 477 download.cgi) tool and converted using the provided ukbconv tool (https://biobank.ctsu.ox.ac.uk/ 478 crystal/refer.cgi?id=149660). Phenotype data was also downloaded for those same individuals using 479 the ukbgene tool. Individuals identified by the UK Biobank to have high heterozygosity, excessive related-480 ness, or an euploidy were removed (1,550 individuals). After then separating individuals into self-identified 481 ancestral groups using data field 21000. Within these cohorts, unrelated individuals were then selected by 482 randomly selecting an individual from each pair of related individuals. This resulted in 349,469 European 483 individuals, 5,716 South Asian individuals, and 4,967 African individuals. 484

Genotype quality control was then performed on each cohort separately using the following steps. All

structural variants were first removed, leaving only single nucleotide polymorphisms in the genotype data. Next, all AT/CG SNPs were removed to avoid possible confounding due to sequencing errors. Then, SNPs with minor allele frequency less than 1% were removed using the plink  $2^{32}$  --maf 0.01. We then removed all SNPs found to be in Hardy-Weinberg equilibrium, using the plink --hwe 0.000001 flag to remove all SNPs with a Fisher's exact test *p*-value >  $10^{-6}$ . Finally, all SNPs with missingness greater than 1% were removed using the plink --mind 0.01 flag.

### <sup>492</sup> Biobank Japan Data

We downloaded summary statistics for 25 quantitative traits from the Biobank Japan (BBJ) website (http: 493 //jenger.riken.jp/en/result)<sup>1,93-95</sup>. The sample descriptions and number of SNPs included in our 494 analyses are given in Table S4. The number of SNPs included in the analysis of each trait represent those 495 SNPs that: (i) contained an rsid number that could be mapped to the hg19 genome build, (ii) overlapped 496 with SNPs contained within the 1000 Genomes Project phase 3 genotype data, and (*iii*) had a minor allele 497 frequency greater than 0.01 in Japanese (JPT) individuals in the 1000 Genomes Project. We used the 1000 498 Genomes phase 3 data from 93 JPT individuals to estimate the linkage disequilibrium (LD) between SNPs 499 in BioBank Japan for which we had the summary statistic data; LD was estimated separately for each of 500 the 25 quantitative traits using the trait specific SNP arrays. LD estimates were used in the calculation of 501 regional association statistics. 502

# <sup>503</sup> Population Architecture using Genomics and Epidemiology (PAGE) Study Data

Summary statistics for genotyped and imputed SNPs in five admixed populations were downloaded from the Population Architecture using Genomics and Epidemiology (PAGE)<sup>6</sup> with permission granted via approval of manuscript proposal. We included summary statistics for up to 14 quantitative traits for African-American, Hispanic and Latin American, Native Hawaiian, American Indian/Alaska Native, and Asian ancestry cohorts when available. All AT/CG SNPs were omitted, and SNPs with an IMPUTE2 information score greater than 0.8 were included in this analysis. Number of individuals and SNPs varied across ancestry-trait combinations and are given in Table S4 - Table S9.

Individuals from the 1000 Genomes Project phase 3<sup>92</sup> and the Human Genome Diversity Panel (HGDP)<sup>108</sup> were used to obtain LD estimates between SNPs for each ancestry cohort. To construct the LD reference panel for PAGE summary statistics from the African-American ancestry cohort, unrelated individuals from the 1000 Genomes Americans of African Ancestry in SW USA (ASW) and African Caribbeans in Barbados (ACB) were used. Only SNPs found in both the 1000 Genomes imputed data and PAGE summary statistics

files were used in gene-level association and heritability analyses. We used the same approach to compute 516 reference LD estimates between SNPs for the Hispanic and Latin American, AIAN, and Asian ancestry 517 cohorts, with the following 1000 Genomes reference population, respectively: Mexican Ancestry from Los 518 Angeles USA (MXL) and Puerto Ricans from Puerto Rico (PUR); Colombians from Medellin, Colombia 519 (CLM) and Peruvians from Lima, Peru (PEL); and the East Asian superpopulation (EAS). For the Native 520 Hawaiian individuals from the PAGE study, there were no appropriate reference populations in the 1000 521 Genomes data. In order to construct a reference LD matrix for the Native Hawaiian ancestry cohort, we 522 randomly sampled individuals from populations in the most recent release of the HGDP proportional to the 523 global ancestry of the Native Hawaiian cohort. The Native Hawaiian cohort's global ancestry proportions 524 were determined using ADMIXTURE runs to be 47.89% Oceanian, 25.16% East Asian, 25.51% European. 525 0.90% African, and 0.54% AIAN in a separate publication (Wojcik preprint - in prep.). We did not sam-526 ple from populations with less than 1% of the total ancestry in the admixture analysis referenced above. 527 The resulting sample from which LD was estimated included 39 individuals from the Papuan Sepik in New 528 Guinea and Melanesian in Bougainville, 14 individuals from the French in France, and 14 individuals from 529 the Yoruba in Nigeria. 530

#### <sup>531</sup> WHI study cohort description

The Women's Health Initiative (WHI) is a long-term, prospective, multi-center cohort study investigating 532 post-menopausal women's health in the US. WHI was funded by the National Institutes of Health and the 533 National Heart, Lung, and Blood Institute to study strategies to prevent heart disease, breast 124 cancer, 534 colon cancer, and osteoporotic fractures in women 50-79 years of age. WHI involves 161,808 women recruited 535 between 1993 and 1998 at 40 centers across the US. The study consists of two parts: the WHI Clinical Trial 536 which was a randomized clinical trial of hormone therapy, dietary modification, and calcium/Vitamin D 537 supplementation, and the WHI Observational Study, which focused on many of the inequities in women's 538 health research and provided practical information about incidence, risk factors, and interventions related 539 to heart disease, cancer, and osteoporotic fractures. For this project, women who self identified as European 540 were excluded from the study sample (dbGaP study accession number: phs000227). 541

#### 542 HCHC/SOL study cohort description

The Hispanic Community Health Study / Study of Latinos (HCHS/SOL) is a multi center study of Hispanic/Latino populations with the goal of determining the role of acculturation in the prevalence and development of diseases, and to identify other traits that impact Hispanic/Latino health. The study is sponsored by the National Heart, Lung, and Blood Institute (NHLBI) and other institutes, centers, and offices of the

National Institutes of Health (NIH). Recruitment began in 2006 with a target population of 16,000 persons 547 of Cuban, Puerto Rican, Dominican, Mexican or Central/South American origin. Household sampling was employed as part of the study design. Participants were recruited through four sites affiliated with San Diego 549 State University, Northwestern University in Chicago, Albert Einstein College of Medicine in Bronx, New 550 York, and the University of Miami. Researchers from seven academic centers provided scientific and logistical 551 support. Study participants who were self-identified Hispanic/Latino and aged 18-74 years underwent ex-552 tensive psycho-social and clinical assessments during 2008-2011. A re-examination of the HCHS/SOL cohort 553 is conducted during 2015-2017. Annual telephone follow-up interviews are ongoing since study inception to 554 determine health outcomes of interest. (dbGaP study accession number: phs000555). 555

#### 556 BioMe Biobank study cohort description

The Charles Bronfman Institute for Personalized Medicine at Mount Sinai Medical Center (MSMC), BioMeTM 557 54 BioBank (BioMe) is an EMR-linked bio-repository drawing from Mount Sinai Medical Center consented 558 patients which were drawn from a population of over 70,000 inpatients and 800,000 outpatients annually. 559 The MSMC serves diverse local communities of upper Manhattan, including Central Harlem (86% African 560 American), East Harlem (88% Hispanic/Latino), and Upper East Side (88% Caucasian/White) with broad 561 health disparities. BioMeTM 58 enrolled over 26,500 participants from September 2007 through August 562 2013, with 25% African American, 36% Hispanic/Latino (primarily of Caribbean origin), 30% Caucasian, 563 and 9% of Other ancestry. The BioMeTM 60 population reflects community-level disease burdens and health 564 disparities with broad public health impact. Biobank operations are fully integrated in clinical care pro-565 cesses, including direct recruitment from clinical sites waiting areas and phlebotomy stations by dedicate 566 Biobank recruiters independent of clinical care providers, prior to or following a clinician standard of care 567 visit. Recruitment currently occurs at a broad spectrum of over 30 clinical care sites. Study participants 568 of self-reported European ancestry were not included in this analysis. (dbGaP study accession number: 569 phs000925). 570

#### 571 MEC study cohort description

The Multiethnic Cohort (MEC) is a population-based prospective cohort study including approximately 215,000 men and women from Hawaii and California. All participants were 45-75 years of age at baseline, and primarily of 5 ancestries: Japanese Americans, African Americans, European Americans, Hispanic/Latinos, and Native Hawaiians. MEC was funded by the National Cancer Institute in 1993 to examine lifestyle risk factors and genetic susceptibility to cancer. All eligible cohort members completed baseline and follow-up questionnaires. Within the PAGE II investigation, MEC proposes to study: 1) diseases for which we have

DNA available for large numbers of cases and controls (breast, prostate, and colorectal cancer, diabetes, 578 and obesity); 2) common traits that are risk factors for these diseases (e.g., body mass index / weight, 579 waist-to-hip ratio, height), and 3) relevant disease-associated biomarkers (e.g., fasting insulin and lipids, 580 steroid hormones). The specific aims are: 1) to determine the population-based epidemiologic profile (al-581 lele frequency, main effect, heterogeneity by disease characteristics) of putative causal SNPs in the five 582 racial/ethnic groups in MEC; 2) for SNPs displaying effect heterogeneity across ethnic/racial groups, we will 583 utilize differences in LD to identify a more complete spectrum of associated SNPs at these loci; 3) investi-584 gate gene x gene and gene x environment interactions to identify modifiers; 4) examine the associations of 585 putative causal SNPs with already measured intermediate phenotypes (e.g., plasma insulin, lipids, steroid 586 hormones); and 5) for SNPs that do not fall within known genes, start to investigate their relationships with 587 gene expression and epigenetic patterns in small genomic studies. For this project, MEC contributed African 588 American, Japanese American, and Native Hawaiian samples. (dbGaP study accession number: phs000220). 589

#### <sup>500</sup> Fine-mapping analyses using the SuSiE framework

To perform SNP-level fine mapping analyses on a given quantitative trait, we applied Sum of Single Effects 591 (SuSiE) variable selection software<sup>34</sup>. SuSiE implements a Bayesian linear regression model on individual 592 level data where sparse prior distributions are placed on the effect size of SNP and posterior inclusion 593 probabilities (PIPs) are used to summarize their statistical relevance to the trait of interest. The software 594 for SuSiE requires an input  $\ell$  which fixes the maximum number of causal SNPs to include in the model. In 595 this work, we consider results when this parameter is chosen conservatively ( $\ell = 3000$ ). We used the three 596 cohorts for which we had genotype data from the UK Biobank (African, European, and South Asian) to 597 test whether there was effect size heterogeneity among ancestries in the 25 traits analyzed in this study. We 598 first selected ten independent, non-overlapping subsamples of 10,000 individuals from the European ancestry 599 cohort and filtered out any SNPs that had a minor allele frequency of less than 0.01. For each subsample, we 600 then applied SuSiE to each of the 25 traits and compared the effect sizes and posterior inclusion probabilities. 601 The average number of SNPs with an effect size greater than 0.01 and average number of SNPs with a PIP 602 greater than 0.01 for each trait across the ten cohorts are reported in Table S11. Table S11 also reports the 603 median correlation coefficient of effect sizes and PIPs among the 45 pairwise comparisons between the 10 604 subsample cohorts. 605

We then applied SuSiE to the African and South Asian ancestry cohorts and compared their resulting effect sizes and PIPs to ten independent, non-overlapping subsamples of the European ancestry cohort. The number of SNPs with an effect size greater than 0.1 and PIPs greater than 0.01 in both the focal cohort (either African or South Asian) and at least one of the ten European ancestry subsamples of the same size
are reported in Table S12 and Table S13. Also reported in these tables, are the mean number of effect sizes
greater than 0.01 and PIPs greater than 0.01 across the European ancestry subsamples for each trait and the
number of unique effect sizes greater than 0.01 and PIPs greater than 0.01 and PIPs greater than 0.01 that were only identified in the
African or South Asian ancestry cohorts. Finally, Table S12 and Table S13 report the median correlation
coefficient of the African or South Asian ancestry cohort effect sizes and PIPs with the ten European ancestry
subsample cohorts of the same size.

#### 616 S1 Description of the gene- $\varepsilon$ framework

A unique feature of gene- $\varepsilon$  is that it treats SNPs with spuriously associated nonzero effects as non-associated. 617 gene- $\varepsilon$  assumes a reformulated null distribution of SNP-level effects  $\tilde{\beta}_j \sim \mathcal{N}(0, \sigma_{\varepsilon}^2)$ , where  $\sigma_{\varepsilon}^2$  is the SNP-618 level null threshold and represents the maximum proportion of phenotypic variance explained (PVE) by a 619 spurious or non-associated SNP. This leads to the reformulated SNP-level null hypothesis  $H_0: \mathbb{E}[\beta_j^2] \leq \sigma_{\varepsilon}^2$ . 620 To infer an appropriate  $\sigma_{\varepsilon}^2$ , gene- $\varepsilon$  fits a K-mixture of normal distributions over the regularized effect sizes 621 with successively smaller variances (i.e.,  $\sigma_1^2 > \cdots > \sigma_K^2 = 0$ ). In this study as in Cheng et al.<sup>38</sup>, we 622 assume that associated SNPs will appear in the first set, while spurious and non-associated SNPs appear 623 in the latter sets. As a final step, gene- $\varepsilon$  computes its gene-level association test statistic for the q-th gene 624 by conformably partitioning the regularized GWA effect size estimates and computing the quadratic form 625  $\tilde{Q}_g = \tilde{\beta}_g^{\intercal} \tilde{\beta}_g$ . Corresponding *p*-values are then derived using Imhof's method. This assumes the common gene-626 level null  $H_0: Q_g = 0$ , where the null distribution of  $Q_g$  is dependent upon the eigenvalues from the scaled 627 LD matrix  $\sigma_{\varepsilon}^{2}\Sigma$ . For details on implementation, validation and performance comparison with simulations, 628 and empirical application to UK Biobank white British individuals in six traits, see Cheng et al.<sup>38</sup>. 629

#### <sup>630</sup> S2 Regression with Summary Statistics (RSS) Enrichment.

1

Consider a GWA study with N individuals typed on P SNPs. For the *j*-th SNP, assume that we are given corresponding effect sizes  $\hat{\beta}_j$  and standard error  $\hat{s}_j$  via a single-SNP linear model fit using OLS. RSS then implements the following likelihood to model the GWA summary statistics<sup>60</sup>

$$\widehat{\boldsymbol{\beta}} \sim \mathcal{N}(\widehat{\mathbf{S}} \widehat{\boldsymbol{\Sigma}} \widehat{\mathbf{S}}^{-1} \boldsymbol{\beta}, \widehat{\mathbf{S}} \widehat{\boldsymbol{\Sigma}} \widehat{\mathbf{S}})$$
(1)

where  $\widehat{\mathbf{S}} = \operatorname{diag}(\widehat{\mathbf{s}})$  is a  $J \times J$  diagonal matrix of standard errors,  $\Sigma$  is again used to represent some empirical estimate of the LD matrix (i.e., using some external reference panel with ancestry matching the cohort of interest), and  $\beta$  are the true (unobserved) SNP-level effect sizes. To model gene-level enrichment, RSS

assumes the following hierarchical prior structure on the true effect sizes

$$\beta_j \sim \pi_j \,\mathcal{N}(0, \sigma_\beta^2) + (1 - \pi_j) \,\delta_0,\tag{2}$$

$$\sigma_{\beta}^{2} = h^{2} \left( \sum_{j=1}^{J} \pi_{j} N^{-1} \widehat{s}_{j}^{-2} \right)^{-1}, \tag{3}$$

$$\pi_j = \left(1 + 10^{-(\theta_0 + a_j\theta)}\right)^{-1},\tag{4}$$

where  $\delta_0$  is point mass centered at zero,  $h^2$  denotes the narrow-sense heritability of the trait,  $a_j$  is an indicator detailing whether the *j*-th SNP is inside a particular gene,  $\theta_0$  is the background proportion of trait-associated SNPs, and  $\theta$  reflects the increase in probability (on the log<sub>10</sub>-odds scale) when a SNP within a gene has non-zero effect. Here, the authors follow earlier works<sup>109</sup> and place independent uniform grid priors on the hyper-parameters { $h^2$ ,  $\theta_0$ ,  $\theta$ }. Note that, unlike other methods, RSS does not calculate a *P*-value for assessing gene-level association. Instead, RSS produces a posterior enrichment probability that at least one SNP in a given gene boundary is associated with the trait

$$P_q := 1 - \Pr\left[\beta_j = 0, \forall j \in \mathcal{J}_q \,|\, \mathbf{D}\right] \tag{5}$$

where **D** represents all of the input data including the GWA summary statistics  $\{\hat{\beta}, \hat{s}\}$ , the estimated LD matrix  $\Sigma$ , and any applicable SNP annotations or weights  $\mathbf{a} = (a_1, \dots, a_J)$ . See<sup>60,110</sup> for more details on preferred hyper-parameter settings. As noted in the main text, RSS is relies on a Markov chain Monte Carlo (MCMC) scheme for sampling posterior distributions and estimating model parameters. As a result, its algorithm can be subject to convergence issues if these (or the random seed) are not chosen properly.

#### <sup>636</sup> S3 SNP-set (Sequence) Kernel Association Test (SKAT).

The implementation of SKAT required access to raw phenotype  $\mathbf{y}$  and genotype  $\mathbf{X}$  information for N individuals typed on J SNPs. To assess enrichment of the  $|\mathcal{J}_g|$  variants within gene g, consider the linear model with sub-matrix  $\mathbf{X}_g$ 

$$\mathbf{y} = \beta_0 + \mathbf{X}_q \boldsymbol{\beta}_q + \mathbf{e}, \qquad \mathbf{e} \sim \mathcal{N}(\mathbf{0}, \tau^2 \mathbf{I})$$
(6)

where  $\beta_0$  is an intercept term,  $\beta_g = (\beta_1, \dots, \beta_{|\mathcal{J}_g|})$  is a vector of regression coefficients for the SNPs within the gene of interest, and **e** is a normally distributed error term with mean zero and scaled variance  $\tau^2$ . For model flexibility, gene-specific SNP effects  $\beta_j$  are assumed to follow an arbitrary distribution with mean

zero and marginal variances  $a_j \sigma_{\beta}^2$ , where  $\sigma_{\beta}^2$  is a variance component and  $a_j$  is a pre-specified weight for the *j*-th SNP. To this end, SKAT uses a variance component scoring approach and tests the null hypothesis  $H_0: \beta = 0$ , or equivalently  $H_0: \sigma_{\beta}^2 = 0$ . The corresponding gene-level test statistic  $\hat{Q}_g$  then takes on the familiar quadratic form

$$\widehat{Q}_g = (\mathbf{y} - \widehat{\beta}_0)^\mathsf{T} \mathbf{K}_g (\mathbf{y} - \widehat{\beta}_0) \tag{7}$$

where  $\hat{\beta}_0$  is the predicted mean of trait under the null hypothesis, and is computed by projecting **y** onto the column space of the intercept (i.e., a vector of ones). The term  $\mathbf{K}_g = \mathbf{X}_g \mathbf{A}_g \mathbf{A}_g \mathbf{X}_g^{\mathsf{T}}$  is commonly referred to as an  $N \times N$  kernel matrix, where  $\mathbf{A}_g = \text{diag}(a_1, \ldots, a_{|\mathcal{J}_g|})$  is used to denote a diagonal weight matrix that changes for each gene g. Each element of  $\mathbf{K}_g$  is computed via the linear kernel function

$$k(\mathbf{x}_i, \mathbf{x}_{i'}) = \sum_{j=1}^{|\mathcal{J}_g|} a_j x_{ij} x_{i'j}.$$
(8)

<sup>637</sup> While implementing SKAT in this work, we follow previous works and set each weight to be  $\sqrt{a_j}$  = <sup>638</sup> Beta(MAF<sub>j</sub>, 1, 25) — the beta distribution density function with pre-specified parameters evaluated at the <sup>639</sup> sample minor allele frequency (MAF) for the *j*-th SNP in the gene region. For more details, see <sup>40,111–113</sup>.

# <sup>640</sup> Clustering traits sharing a core set of associated genes using the WINGS algo-<sup>641</sup> rithm

We used the WINGS algorithm<sup>114</sup> to identify clusters of traits sharing a core set of genes enriched for 642 associated mutations. WINGS takes as input a gene (M) by trait (N) matrix and uses the Ward distance 643 metric to find the distance among vectors of gene scores for different phenotypes; in this study, we used 644 gene- $\varepsilon$  gene-level association statistics as the input to WINGS. The more significantly associated genes that 645 two traits share, the closer they will be in the gene-dimensional space. Applying WINGS to a matrix of 646 gene scores for each ancestry separately, we examined whether the same traits clustered together, separately 647 in each ancestry. We constructed matrices of gene- $\varepsilon$  gene-level association statistics for the UK Biobank 648 European, African, South Asian (from the UK Biobank) and East Asian (Biobank Japan) ancestry cohorts. 649 Each of these matrices contained gene-level association statistics for all 25 quantitative traits of interest. 650 The total number of genes and regulatory regions included were: European (23,603), African (23,575), 651 South Asian(23,671), and East Asian (21,435). For the East Asian ancestry cohort, we limited the genes 652 to the intersection of genes with gene- $\varepsilon$  gene-level association statistics across all 25 traits. The number 653 of gene scores calculated for each trait in the East Asian ancestry cohort varies due to the heterogeneity 654

in imputed and genotype SNP arrays in the Biobank Japan studies (Table S4 and Table S15). Figure S19
shows the resulting dendrograms displaying prioritized phenotypes identified using the WINGS algorithm on
each cohort's gene score matrix. The WINGS algorithm is designed to run on 25 phenotypes or more (see
McGuirl et al. <sup>114</sup> for details), and we therefore did not apply the WINGS algorithm to the AIAN, Native
Hawaiian, or Hispanic and Latin American cohorts as there was not data for enough phenotypes (Table
S5-Table S9).

## <sup>661</sup> Analysis of GWAS Catalog Metadata and Previous GWA Publications

We cross-referenced our results from association testing at multiple genomic scales against previously published results in the GWAS catalog (https://www.ebi.ac.uk/gwas/) and in PubMed using the following processes.

In order to collect PubMed IDs (PMIDs) for publications associated with the UK Biobank, a two-part 665 data collection process was used. The first process was to directly search for publications with variations 666 of the term "UK Biobank" (e.g., U.K. Biobank, United Kingdom Biobank) from PubMed using the Entrez 667 Programming Utilities (E-Utilities) API. The E-Utilities API is the public API to the NCBI Entrez sys-668 tem and allows direct access to all Entrez databases including PubMed. Search queries were formulated by 669 narrowing publications using year published and then further narrowing to those publications with varia-670 tions of the search term "UK Biobank" in either the title or abstract. The open-source Python package 671 Entrez (https://biopython.org/DIST/docs/api/Bio.Entrez-module.html) from the Biopython Project 672 was used to facilitate interaction with the E-Utilities API. 673

The second data collection process was to gather information from publications listed directly on the UK 674 Biobank website (https://www.ukbiobank.ac.uk/). Since the majority of publications on the website did 675 not have an easily accessible PMID, identifying information including publication title and year was scraped 676 and used to retrieve a publication's corresponding PMID (again using the E-Utilities API). The HTML/XML 677 document parsing Python library Beautiful Soup (https://www.crummy.com/software/BeautifulSoup/ 678 bs4/doc/) was used to parse the HTML of the various UK Biobank webpages, and the Python Requests 679 library (https://requests.readthedocs.io/en/master/) was used to programatically send HTTP calls 680 to the server hosting the website. PMIDs were retrieved directly from the XML output of the E-Utilities 681 API calls. 682

The PMIDs retrieved from both processes were aggregated into a single set of unique PMIDs, as some publications were identified by both processes. Publications that could not get associated PMIDs from the second data collection process were flagged for manual processing. The PMIDs that were retrieved from

PubMed directly but could not be found based on the publication information provided on the UK Biobank website were noted. Conversely, the PMIDs that could be retrieved from publication information found on the UK Biobank website but not directly from PubMed were also noted.

Using the compiled list of PMIDs, analyses of the UK Biobank data set reported in the GWAS catalog association data were compiled. Previous genotype-to-phenotype association data and sample ancestry descriptions were downloaded from https://www.ebi.ac.uk/gwas/docs/file-downloads. Unique genotype-to-phenotype associations were parsed using a set of custom python scripts. All scripts used in the curation of PMIDs, parsing of GWAS catalog summary data, and determination of previously published genotype-to-phenotype associations from UK Biobank studies are available on GitHub (https: //github.com/ramachandran-lab/redefining\_replication).

# Simulation design to test the power and false discovery rate of GWA and gene level association analyses

#### <sup>698</sup> Simulations of a single population

In our simulation studies, we used the following general simulation scheme to generate quantitative traits 699 using real genotype data on chromosome 1 from N randomly sampled individuals of European ancestry in 700 the UK Biobank. This pipeline follows from previous studies  $^{38,78}$ . We will use **X** to denote the  $N \times J$ 701 genotype matrix, with J denoting the number of single nucleotide polymorphisms (SNPs) encoded as 0, 1, 2702 copies of a reference allele at each locus and  $\mathbf{x}_i$  representing the genotypic vector for the *j*-th SNP. Following 703 quality control procedures detailed in the Supplemental Information, our simulations included J = 36,518704 SNPs distributed across genome. We used the NCBI's RefSeq database in the UCSC Genome Browser to 705 assign SNPs to genes which resulted in G = 1,408 genes in the simulation studies. 706

After the annotation step, we simulated phenotypes by first assuming that the total phenotypic variance  $\mathbb{V}[\mathbf{y}] = 1$ , and that all observed genetic effects explained a fixed proportion of this value (i.e., narrow-sense heritability,  $h^2$ ). Next, we randomly selected a certain percentage of genes to be enriched for associations and denoted the sets of SNPs that they contained as C. Within C, we selected causal SNPs in a way such that each associated gene at least contains one SNP with non-zero effect size. Quantitative continuous traits were then generated under the following two general linear models:

• Standard Model: 
$$\mathbf{y} = \sum_{c \in \mathcal{C}} \mathbf{x}_c \beta_c + \mathbf{e}$$

• Population Structure Model:  $\mathbf{y} = \mathbf{W}\mathbf{b} + \sum_{c \in \mathcal{C}} \mathbf{x}_c \beta_c + \mathbf{e}$ 

where  $\mathbf{y}$  is an N-dimensional vector containing all the phenotype states;  $\mathbf{x}_c$  is the genotype for the c-th

causal SNP;  $\beta_c$  is the additive effect size for the *c*-th SNP; and  $\mathbf{e} \sim \mathcal{N}(0, \tau^2 \mathbf{I})$  is an *N*-dimensional vector 716 of normally distributed environmental noise. Additionally, in the model with population structure, W is an 717  $N \times M$  matrix of the top M = 10 principal components (PCs) from the genotype matrix and represents 718 additional population structure with corresponding fixed effects **b**. The effect sizes of SNPs in genes enriched 719 for associations are randomly drawn from standard normal distributions and then rescaled so they explain 720 a fixed proportion of the narrow-sense heritability  $\mathbb{V}[\sum \mathbf{x}_c \beta_c] = h^2$ . The coefficients for the genotype PCs 721 are also drawn from standard normal distributions and rescaled such that  $\mathbb{V}[\mathbf{Wb}] = 10\%$  of the total 722 phenotypic variance, with the variance of all non-genetic effects contributing  $\mathbb{V}[\mathbf{Wb}] + \mathbb{V}[\mathbf{e}] = (1 - h^2)$ . For 723 any simulations conducted under the population structure model, genotype PCs are not included in any of 724 the model fitting procedures, and no other preprocessing normalizations were carried out to account for the 725 additional population structure. More specifically, GWA summary statistics are then computed by fitting a 726 single-SNP univariate linear model via ordinary least squares (OLS): 727

$$\widehat{\beta}_j = (\mathbf{x}_j^\mathsf{T} \mathbf{x}_j)^{-1} \mathbf{x}_j^\mathsf{T} \mathbf{y}; \tag{9}$$

for every SNP in the data j = 1, ..., J. These OLS effect size estimates, along with an empirically LD matrix  $\Sigma$  computed directly from the full  $N \times J$  genotype matrix **X**, are given to gene- $\varepsilon$ . We also retain standard errors and *p*-values for the implementation of competing methods: RSS<sup>60</sup>, SKAT<sup>40</sup>, and the standard GWA SNP-level association test. Given the simulation procedure above, we simulate a wide range of scenarios for comparing the performance of gene-level association approaches by varying the following parameters:

- Number of individuals: N = 5,000 and 10,000;
- Narrow-sense heritability:  $h^2 = 0.2$  and 0.6;

#### • Percentage of enriched genes: 1% (sparse) and 10% (polygenic);

Furthermore, we set the number of causal SNPs with non-zero effects to be some fixed percentage of all SNPs 736 located within the designated genes enriched for associations. We set this percentage to be 0.125% in the 737 1% associated SNP-set case, and 3% in the 10% associated SNP-set case. All performance comparisons are 738 based on 100 different simulated runs for each parameter combination. Lastly, for each simulated dataset, 739 we also selected some number of intergenic SNPs (i.e., SNPs not mapped to any gene) to have non-zero 740 effect sizes. This was done to mimic genetic associations in unannotated regulatory elements. Specifically, 741 five randomly selected intergenic SNPs were given non-zero contributions to the trait heritability in the 1% 742 enriched genes case, and 30 intergenic SNPs were selected in the 10% enriched genes case. 743

All performance comparisons are based on 100 different simulated runs for each parameter combination. We computed gene-level *p*-values for gene- $\varepsilon$ , SKAT, and the single-SNP GWAS. For evaluating the performance of RSS, we compute posterior enrichment probabilities. For all approaches, we assessed the power and false discovery rates when identifying enriched genes at either a Bonferroni-corrected threshold (p = 0.05/1, 408 genes =  $3.55 \times 10^{-5}$ ) or according to the median probability model (posterior enrichment probability > 0.5)<sup>115</sup>. Figure S4 and Figure S5 show the mean performances (and standard errors) across all simulated replicates.

#### 751 Simulations of genetic trait architecture in two populations

We used the African (UKB) cohort and a subset of the European cohort and simulation studies to test the 752 ability of GWAS and gene- $\varepsilon$  to detect shared causal SNPs (in the case of gene- $\varepsilon$ , genes containing causal 753 SNPs) in a multi-ancestry study. Using the same simulation protocol as that described for testing power of 754 different enrichment analysis methods, described in Simulations in a single population, we labeled all genes 755 containing at least one causal SNP as "causal". We first determined the power of gene- $\varepsilon$  to identify SNPs or 756 genes that are causal in each cohort under a variety of genomic architectures. The total amount of variance 757 explained in the phenotype by the causal SNPs (i.e. the narrow-sense heritability) to be equal to 0.2 or 758 0.6. In each of these contexts, the sparsity of causal variants as a function of the total number of variants 759 was set to either 0.1 or 0.5. These values of causal SNP sparsity were selected in order to ensure that an 760 ample number of SNPs were associated with the phenotype in both cohorts. Finally, the overlap in causal 761 SNPs between the two cohorts was tested at proportions equal to 0 (no overlap in causal between SNPs 762 cohorts) 0.25, 0.5, and 1 (complete overlap in causal SNPs between cohorts). For each of these parameter 763 sets, 50 replicate simulations were performed of two cohorts derived from 10,000 European individuals and 764 4,967 African individuals, respectively. We summarize the performance of the standard GWA framework 765 and gene- $\varepsilon$  across the parameter space. Generally, gene- $\varepsilon$  performs better on the European cohort than it 766 does in the African cohort, but is better powered in the African cohort when the causal SNPs are the same 767 in both cohorts (Figure S6 and Figure S7). Additionally, gene- $\varepsilon$  performs better when identifying causal 768 genes that are shared between the two cohorts - particularly when traits have high heritability Figure S8 -769 Figure S9. 770

## 771 Appendix

#### 772 S4 SNP-level results for height and C-reactive protein

In Figure S3a and Figure S3d, we found that, across 25 traits analyzed, height had the greatest number of genome-wide significant SNP-level associations (76,910 unique associations) in at least one ancestry. Of these SNP-level associations, 8.90% (7,377 SNPs) replicate based off of rsID in at least two ancestry cohorts. Height is not the only trait in which the standard GWA SNP-level association test detects associations that replicate extensively across ancestries. In fact, SNP-level associations replicate in each of the 25 continuous traits that we analyze in this study.

We analyzed SNP-level associations with C-reactive protein in six ancestry cohorts: African-American 779 (PAGE), European, South Asian, East Asian, Native Hawaiian, and Hispanic and Latin American cohorts. 780 C-reactive protein is an example of a trait with a sparse and highly conserved genetic architecture across 781 ancestries, as shown in Figure 2. Many SNPs within the CRP gene have been previously associated with 782 C-reactive protein plasma levels  $^{116-118}$ . In our analysis, rs3091244 is genome-wide significant in only the 783 European ancestry cohort, and has been functionally validated as influencing C-reactive protein levels<sup>52,53</sup>. 784 The SNP rs3091244 is located in a promoter region slightly upstream of CRP, and it has clinical implications 785 for both atrial fibrillation<sup>119</sup> and lupus erythematosus<sup>120</sup> (European  $p = 1.54 \times 10^{-116}$ ; East Asian p =786  $1.15 \times 10^{-9}$ ). 787

We expanded our search for replicated GWA SNP-level association signals across ancestry cohorts by 788 scanning for 1 Mb regions that contained associations to the same phenotype in two or more ancestries— 789 a process often referred to as "clumping". These windows were centered at every unique genome-wide 790 significant SNP in any ancestry for a given trait (we refer the 1Mb window around the significant SNP as a 791 "clump", Figure S3b and Figure S3e). In addition to the largest number of unique SNP-level associations, 792 height also had the largest proportion of clumps containing a significant SNP-level GWA association signal 793 that replicated in at least two ancestry cohorts (see Figure S3b and Figure S3e). The three traits with the 794 greatest proportion of clumps containing SNP-level GWA signals that replicate in multiple ancestry cohorts 795 were height (77.09% of clumps), urate (65.89%), and low density lipoprotein (54.40%). 796

In addition to the SNP-level associations on chromosome 1 surrounding the *CRP* gene across all six ancestry cohorts (displayed in Figure 2), there are other regions of the genome that contain significant GWA associations with C-reactive protein that replicate in multiple ancestry cohorts. On chromosome 2, there is a cluster of four SNPs significantly associated with C-reactive protein levels in the European, East Asian, and Hispanic and Latin American ancestry cohorts. Of these, rs1260326 (European  $p = 1.01 \times 10^{-55}$ ; East Asian  $p = 1.70 \times 10^{-9}$ ; Hispanic and Latin American  $p = 1.24 \times 10^{-20}$ ), rs780094 (European  $p = 9.95 \times 10^{-51}$ ; East Asian  $p = 1.70 \times 10^{-9}$ ; Hispanic and Latin American  $p = 1.14 \times 10^{-16}$ ), and rs6734238 (African-American (PAGE)  $p = 3.04 \times 10^{-10}$ ; European  $p = 8.38 \times 10^{-34}$ ; South Asian  $p = 2.17 \times 10^{-9}$ ) were statistically significant in three of the six ancestry cohorts that we analyzed. Each of these three SNPs has been previously associated with C-reactive protein levels in a European ancestry cohort<sup>121-123</sup>. Of these three SNPs, only one (rs6734238) had previously been replicated in other ancestries (in African-American, and Hispanic and Latin American cohorts<sup>124</sup>).

On chromosome 19 there are 23 SNPs that are associated with CRP in the African-American PAGE, 809 European, and Hispanic and Latin American ancestry cohorts. Two other SNPs are associated with C-810 reactive protein in the African-American (PAGE), European, and Hispanic and Latin American cohorts, 811 as well as the East Asian ancestry cohort. One of these two SNPs, rs7310409 (African-American (PAGE) 812  $p = 8.57 \times 10^{-9}$ ; European  $p = 3.57 \times 10^{-210}$ ; East Asian  $p = 2.72 \times 10^{-27}$ ; Hispanic and Latin American  $p = 1.57 \times 10^{-27}$ ; Hispanic an  $p = 1.57 \times 10^{-27}$ ; Hispanic an  $p = 1.57 \times 10^{-27}$ ; 813  $5.35 \times 10^{-29}$ ) located in the HNF1 homeobox A (*HNF1A*) gene, has been previously associated with C-reactive 814 protein levels in only a European ancestry cohort<sup>122,123</sup>. Three additional significant SNPs in our analysis 815 have been previously associated with European ancestry cohorts in previous studies, including:  $rs1169310^{124}$ 816 (European  $p = 1.52 \times 10^{-172}$ ; East Asian  $p = 1.28 \times 10^{-18}$ ; Hispanic and Latin American  $p = 1.17 \times 10^{-27}$ ), 817 rs1183910<sup>121,125</sup> (European  $p = 5.50 \times 10^{-177}$ ; East Asian  $p = 3.16 \times 10^{-29}$ ; Hispanic and Latin American 818  $p = 7.47 \times 10^{-29}$ , and rs7953249<sup>126</sup> (European  $p = 1.19 \times 10^{-177}$ ; East Asian  $p = 1.10 \times 10^{-19}$ ; Hispanic 819 and Latin American  $p = 4.80 \times 10^{-29}$ ). Two SNPs, rs2259816 (European  $p = 2.77 \times 10^{-172}$ ; East Asian 820  $p = 9.33 \times 10^{-18}$ ; Hispanic and Latin American  $p = 1.90 \times 10^{-27}$ ) and rs7979473 (African  $p = 1.49 \times 10^{-9}$ ; 821 East Asian  $p = 6.06 \times 10^{-29}$ ; Hispanic and Latin American  $p = 1.56 \times 10^{-30}$ ), have been previously associated 822 with C-reactive protein in both African-American and Hispanic and Latin American ancestry cohorts<sup>124</sup>. 823 There is one final group of three SNPs associated with C-reactive protein in the African-American (PAGE), 824 European, East Asian, and Hispanic and Latin American ancestry cohorts on chromosome 19. One of them, 825 rs4420638 (East Asian  $p = 9.93 \times 10^{-29}$ ; Hispanic and Latin American  $p = 2.03 \times 10^{-30}$ ), has been previously 826 associated in a European ancestry cohort<sup>121,123,125</sup>. These four regions indicate a highly conserved SNP-827 level architecture of C-reactive protein across six ancestry cohorts. Interestingly, we were unable to replicate 828 associations with C-reactive protein across ancestries at the gene or pathway levels. 829

# <sup>330</sup> Gene and pathway association results

Three genes, GP6, RDH13, and AGPAT5, were significantly associated with platelet count (PLC) in the African-American (PAGE) ancestry cohort and the East Asian ancestry cohort (Figure S10. Of these, no significant SNPs in the glycoprotein VI platelet (GP6) gene have been reported in the GWAS catalog for

either ancestry cohort. However, a single SNP within GP6, rs1613662, has previously been associated with 834 mean platelet volume in a GWA study analyzing a European ancestry cohort<sup>127</sup>. GP6 plays a critical 835 role in platelet aggregation, and mutations have been previously associated with fetal loss<sup>128</sup>. The retinol 836 dehydrogenase 13 (RDH13) gene has no reported GWAS catalog associations with platelet count, but is 837 within 60kb of a SNP significantly associated with platelet aggregation<sup>129</sup>. Of the three genes significantly 838 associated with PLC in both the European and AIAN cohorts, 1-Acylglycerol-3-Phosphate O-Acyltransferase 839 5 (AGPAT5) is a member of a gene family known to play a role in immunity and inflammation response<sup>130</sup>. 840 Alcohol dehydrogenase 2 (ALDH2) has additionally been associated with hypertension in an elderly 841 Japanese cohort<sup>131</sup>. A member of the RAS oncogene family (RAB8A) has been shown to play a role in the 842 inhibition of inflammatory response. In contrast, the cut like homeobox 2 CUX2 gene contains a significantly 843 associated SNP in the array used in this study for the East Asian ancestry cohort, but it has no previous 844 associations in a European ancestry cohort. However, CUX2 is significantly associated at the gene-level in 845 both the European and East Asian ancestry cohorts. Although not reported as being associated with PLC 846 in the GWAS Catalog, a single SNP, rs61745424 which encodes a missense mutation, has been previously 847 identified as being related to the trait<sup>132</sup>. The gene- $\varepsilon$  association statistics for the seven genes significantly 848 associated with PLC are available in Table S17. 849

Finally, a single gene, acyl-CoA dehydrogenase family member 10 (*ACAD10*) associated in our gene-level analysis of PLC, was significant in both the European and East Asian ancestry cohorts (European gene- $\varepsilon p = 1.47 \times 10^{-10}$ ; East Asian gene- $\varepsilon p = 2.00 \times 10^{-10}$ ) but contained no previous associations in the GWAS catalog. The African-American and Hispanic and Latin American ancestry cohorts analyzed in Qayyum et al. <sup>133</sup> both contain SNPs within *ACAD10* that are significantly associated with PLC.

In our analysis of triglyceride levels in six ancestry cohorts (African-American (PAGE), European, East 855 Asian, South Asian, Hispanic and Latin American, and Native Hawaiian), we identified shared genetic 856 architecture at the SNP, gene, and subnetwork level. Replicated SNPs and genes between the six ancestry 857 cohorts are shown in Figure S12-Figure S13. We focus our discussion of results at the network level in 858 the European, East Asian, and Native Hawaiian ancestry cohorts (Figure 3). In the European and East 859 Asian ancestry cohorts, we identified 55 shared genome-wide significant associations at the gene-level. Of 860 these results, eight genes lie in the same significantly mutated subnetwork (Hierarchical HotNet  $p < 10^{-3}$ ) 861 when analyzing each ancestry cohort independently. Five of those eight genes belong to the apolipoprotein 862 family of genes, including: apolipoprotein A1 (APOA1), apolipoprotein A4 (APOA4), apolipoprotein A5 863 (APOA5), apollipoprotein C3 (APOC3), apolipoprotein E (APOE). Specifically, the apolipoprotein play a 864 central role in lipoprotein biosynthesis and transport. All of these genes contain SNPs previously associated 865 with triglyceride levels in a European ancestry  $cohort^{98-103}$ . All five genes also contain SNPs previously

associated with triglyceride levels in non-European ancestry cohorts. Specifically, APOA1, APOC3, and APOE each contain SNPs previously associated with triglyceride levels in African-American and Hispanic and Latin American ancestry cohorts <sup>98,99</sup>. The APOA5 gene has previously been associated to triglyceride levels in an East Asian, African-American, and Hispanic and Latin American ancestry cohorts <sup>100,104</sup>.

The other three genes that were significantly associated with triglyceride levels in the European and 871 East Asian ancestry cohorts are members of the largest significantly mutated subnetwork including phos-872 pholipid transfer protein (*PLTP*; European gene- $\varepsilon p = 4.29 \times 10^{-9}$ ; East Asian gene- $\varepsilon p = 6.66 \times 10^{-15}$ ), 873 lipoprotein lipase (LPL; European gene- $\varepsilon p = 4.08 \times 10^{-13}$ ; East Asian gene- $\varepsilon p = 1.00 \times 10^{-20}$ ), and 874 angiopoietin like 3 (ANGPTL3; European gene- $\varepsilon p = 8.86 \times 10^{-8}$ ; East Asian gene- $\varepsilon p = 1.00 \times 10^{-20}$ ). 875 PLTP has previously been associated with triglyceride levels in European, African-American, and Hispanic 876 and Latin American ancestry cohorts 97-100,105-107,134. LPL is one of the most well-studied genes in the 877 regulation of triglyceride levels. It has previously been associated with triglyceride levels in European an-878 cestry cohorts<sup>96-103,105-107,134,134-146</sup>, East Asian ancestry cohorts<sup>104,147</sup>, and African ancestry cohorts as 879 well as Hispanic and Latin American ancestry cohorts<sup>96–98,100,105,145,146,148,149</sup>. The final gene that was 880 genome-wide significant in both the European and East Asian ancestry cohorts, ANGPTL3, has no previ-881 ous associations in the GWAS catalog and presents a novel candidate gene within the network. While not 882 significant in any gene-level analysis, the gene ANGPTL4 (European gene- $\varepsilon p = 1.00 \times 10^{-20}$ ; East Asian 883 gene- $\varepsilon p = 9.99 \times 10^{-1}$  from the same family is present in the largest subnetwork in the European cohort 884 and also has also been previously identified as having associations in European, African, and Hispanic and 885 Latin American ancestry cohorts<sup>96,97,100,145,146,150</sup>. 886

In our analysis of the European ancestry cohort from the UK Biobank, we additionally identified a set of 887 eight genes that are connected to the core network discussed above. One of these genes is ANGPTL4, which 888 we discussed above. Five of these genes were significant at the gene-level in the European ancestry cohort, 889 including four apoliprotein genes (APOC1; European gene- $\varepsilon p = 1.67 \times 10^{-16}$ , APOC2; European gene-890  $\varepsilon p = 3.57 \times 10^{-13}$ , APOC4; European gene- $\varepsilon p = 3.72 \times 10^{-13}$ , and APOB; European gene- $\varepsilon p = 1.00 \times 10^{-20}$ ) 891 and lipase maturation factor 1 (LMF1; European gene- $\varepsilon p = 8.03 \times 10^{-7}$ ). Each of these genes have been 892 previously associated with triglyceride levels in a European ancestry cohort<sup>100</sup>. Additional associations 803 were also found in that same study which conducted a meta-analysis of European, African-American, and 894 Hispanic and Latin American ancestry cohorts. The final two genes included in the significantly mutated 895 subnetwork of the European ancestral cohort, APOL1 and HBA1, were not were not identified as genome-896 wide significant by gene- $\varepsilon$  and have no previous SNP-level associations with triglyceride levels in the GWAS 897 Catalog. Interestingly, both APOL1 (Native Hawaiian gene- $\varepsilon p = 8.89 \times 10^{-11}$ ) and HBA1 (Native Hawaiian 898 gene- $\varepsilon p = 2.46 \times 10^{-10}$ ) were both identified as genome-wide significant by gene- $\varepsilon$  in our analysis of the Native

Hawaiian ancestry cohort and the interaction between them was identified in our Hierarchical HotNet<sup>31</sup>
 analysis as present in both the European and Native Hawaiian ancestry cohorts.

In addition to APOL1 and HBA1, six more genes are connected to the core network of genes that overlap in the East Asian and European significantly mutated subnetworks. Of these, both HBA2 and B4GALT3 are significant at the gene-level in the Native Hawaiian ancestry cohort alone. They are each connected to genes identified in both the European and Native Hawaiian ancestry cohorts as members of the largest significantly mutated subnetwork. The final three genes include kallikrein related peptidase 8 (KLK8), pancreatic lipase PNLIP, and wnt family member 4 (WNT4) which were not significant at the gene-level and did not contain previous SNP-level associations in the GWAS catalog.

In the largest significantly mutated subnetwork identified in our analysis of the East Asian ancestry 909 cohort, we identified seven genes that were not shared by the networks in other ancestry cohorts. One of these 910 genes, beta-secretase 1 (BACE1; East Asian gene- $\varepsilon p = 3.57 \times 10^{-13}$ ; European gene- $\varepsilon p = 5.55 \times 10^{-17}$ ), 911 was significant at the gene-level but contained no previously associated SNPs in any cohort in the GWAS 912 catalog. BACE1 plays a role in the metabolism of amyloid beta precursor protein<sup>151</sup>. Three of the genes 913 within the network identified in the East Asian ancestry cohort contain previously associated SNPs in 914 both European and non-European ancestry cohorts, including: cholesteryl ester transfer protein (CETP), 915 proprotein convertase subtilisin/kexin type 6 (PCSK6), and proprotein convertase subtilisin/kexin type 7 916  $(PCSK7)^{98,105}$ . The final three genes in the significantly mutated subnetwork identified in the East Asian 917 ancestry cohort were not significant at the gene-level and do not contain previously associated SNPs in the 918 GWAS catalog in any ancestral cohort. Lecithin-cholesterol acyltransferase (LCAT) is involved in cholesterol 919 biosynthesis and apolipoprotein F(APOF) encodes one of the minor apolipoprotein genes present in plasma. 920 Finally, tyrosine-protein kinase receptor 3(TYRO3) plays a role in ligand recognition and cell metabolism<sup>152</sup>. 921 The gene- $\varepsilon$  *p*-values in each ancestry cohort for each of the 28 genes discussed here are shown in Table S18. 922

## 923 **References**

[1] Akiko Nagai, Makoto Hirata, Yoichiro Kamatani, Kaori Muto, Koichi Matsuda, Yutaka Kiyohara,
 Toshiharu Ninomiya, Akiko Tamakoshi, Zentaro Yamagata, Taisei Mushiroda, et al. Overview of the
 biobank japan project: study design and profile. Journal of epidemiology, 27(Supplement\_III):S2–S8,
 2017.

[2] Alicia R Martin, Christopher R Gignoux, Raymond K Walters, Genevieve L Wojcik, Benjamin M
 Neale, Simon Gravel, Mark J Daly, Carlos D Bustamante, and Eimear E Kenny. Human demographic

930	history impacts genetic risk prediction across diverse populations.	The American Journal of	of Human
931	Genetics, 100(4):635–649, 2017.		

- [3] Pamela L Sankar and Lisa S Parker. The precision medicine initiative's all of us research program: an 932 agenda for research on its ethical, legal, and social issues. Genetics in Medicine, 19(7):743–750, 2017. 933 [4] Clare Bycroft, Colin Freeman, Desislava Petkova, Gavin Band, Lloyd T Elliott, Kevin Sharp, Allan 934 Motyer, Damjan Vukcevic, Olivier Delaneau, Jared O'Connell, et al. The uk biobank resource with 935 deep phenotyping and genomic data. Nature, 562(7726):203-209, 2018. 936 [5] Alicia R Martin, Masahiro Kanai, Yoichiro Kamatani, Yukinori Okada, Benjamin M Neale, and Mark J 937 Daly. Clinical use of current polygenic risk scores may exacerbate health disparities. Nature genetics, 938 51(4):584, 2019.939 [6] Genevieve L Wojcik, Mariaelisa Graff, Katherine K Nishimura, Ran Tao, Jeffrey Haessler, Christo-940
- pher R Gignoux, Heather M Highland, Yesha M Patel, Elena P Sorokin, Christy L Avery, et al. Genetic
  analyses of diverse populations improves discovery for complex traits. <u>Nature</u>, 570(7762):514–518, 2019.
- [7] Mashaal Sohail, Robert M Maier, Andrea Ganna, Alex Bloemendal, Alicia R Martin, Michael C
   Turchin, Charleston WK Chiang, Joel Hirschhorn, Mark J Daly, Nick Patterson, et al. Polygenic
   adaptation on height is overestimated due to uncorrected stratification in genome-wide association
   studies. Elife, 8:e39702, 2019.
- [8] Jeremy J Berg, Arbel Harpak, Nasa Sinnott-Armstrong, Anja Moltke Joergensen, Hakhamanesh
   Mostafavi, Yair Field, Evan August Boyle, Xinjun Zhang, Fernando Racimo, Jonathan K Pritchard,
   et al. Reduced signal for polygenic adaptation of height in uk biobank. Elife, 8:e39725, 2019.
- [9] Pak C Sham and Shaun M Purcell. Statistical power and significance testing in large-scale genetic
   studies. Nature Reviews Genetics, 15(5):335–346, 2014.
- [10] Alkes L Price, Chris CA Spencer, and Peter Donnelly. Progress and promise in understanding the
   genetic basis of common diseases. <u>Proceedings of the Royal Society B: Biological Sciences</u>, 282(1821):
   20151684, 2015.
- [11] Peter M Visscher, Naomi R Wray, Qian Zhang, Pamela Sklar, Mark I McCarthy, Matthew A Brown,
   and Jian Yang. 10 years of gwas discovery: biology, function, and translation. <u>The American Journal</u>
   of Human Genetics, 101(1):5–22, 2017.

- [12] Jonathan K Pritchard and Molly Przeworski. Linkage disequilibrium in humans: models and data.
   The American Journal of Human Genetics, 69(1):1–14, 2001.
- [13] Jeremy J Berg and Graham Coop. A population genetic signal of polygenic adaptation. <u>PLoS Genet</u>,
   10(8):e1004412, 2014.
- [14] Mattias Jakobsson, Michael D Edge, and Noah A Rosenberg. The relationship between fst and the
   frequency of the most frequent allele. Genetics, 193(2):515–528, 2013.
- <sup>964</sup> [15] Michael D Edge and Noah A Rosenberg. Upper bounds on fst in terms of the frequency of the most
   <sup>965</sup> frequent allele and total homozygosity: the case of a specified number of alleles. <u>Theoretical population</u>
   <sup>966</sup> biology, 97:20-34, 2014.
- [16] Michael D Edge and Noah A Rosenberg. A general model of the relationship between the apportionment
   of human genetic diversity and the apportionment of human phenotypic diversity. <u>Human biology</u>, 87
   (4):313–337, 2015.
- [17] Farhad Hormozdiari, Anthony Zhu, Gleb Kichaev, Chelsea J-T Ju, Ayellet V Segrè, Jong Wha J
   Joo, Hyejung Won, Sriram Sankararaman, Bogdan Pasaniuc, Sagiv Shifman, et al. Widespread allelic
   heterogeneity in complex traits. The American Journal of Human Genetics, 100(5):789–802, 2017.
- [18] John Novembre and Nicholas H Barton. Tread lightly interpreting polygenic tests of selection. <u>Genetics</u>,
   208(4):1351, 2018.
- [19] Noah A Rosenberg, Michael D Edge, Jonathan K Pritchard, and Marcus W Feldman. Interpreting
   polygenic scores, polygenic adaptation, and human phenotypic differences. Evolution, medicine, and
   public health, 2019(1):26–34, 2019.
- <sup>978</sup> [20] Arbel Harpak and Molly Przeworski. The evolution of group differences in changing environments.
   <sup>979</sup> PLoS Biology, 19(1):e3001072, 2021.
- [21] Luisa Pereira, Leon Mutesa, Paulina Tindana, and Michèle Ramsay. African genetic diversity and
   adaptation inform a precision medicine agenda. Nature Reviews Genetics, 2021.
- [22] Arun Durvasula and Kirk E Lohmueller. Negative selection on complex traits limits phenotype pre diction accuracy between populations. The American Journal of Human Genetics, 2021.
- [23] Hakhamanesh Mostafavi, Arbel Harpak, Ipsita Agarwal, Dalton Conley, Jonathan K Pritchard, and
   Molly Przeworski. Variable prediction accuracy of polygenic scores within an ancestry group. <u>Elife</u>, 9:
   e48376, 2020.

75

987 988	[24]	Chief Ben-Eghan, Rosie Sun, Jose Sergio Hleap, Alex Diaz-Papkovich, Hans Markus Munter, Audrey V Grant, Charles Dupras, and Simon Gravel. Don't ignore genetic data from minority populations, 2020.
989 990	[25]	Alice B Popejoy and Stephanie M Fullerton. Genomics is failing on diversity. <u>Nature News</u> , 538(7624): 161, 2016.
991 992	[26]	Carlos D Bustamante, M Francisco, and Esteban G Burchard. Genomics for the world. <u>Nature</u> , 475 (7355):163–165, 2011.
993 994 995	[27]	Nasa Sinnott-Armstrong, Yosuke Tanigawa, David Amar, Nina J Mars, Matthew Aguirre, Guhan Ram Venkataraman, Michael Wainberg, Hanna M Ollila, James P Pirruccello, Junyang Qian, et al. Genetics of 38 blood and urine biomarkers in the uk biobank. <u>BioRxiv</u> , page 660506, 2019.
996 997	[28]	Evan A Boyle, Yang I Li, and Jonathan K Pritchard. An expanded view of complex traits: from polygenic to omnigenic. <u>Cell</u> , 169(7):1177–1186, 2017.
998 999 1000	[29]	Nasa Sinnott-Armstrong, Sahin Naqvi, Manuel A Rivas, and Jonathan K Pritchard. Gwas of three molecular traits highlights core genes and pathways alongside a highly polygenic background. <u>eLife</u> , 2021.
1001 1002	[30]	Iain Mathieson. The omnigenic model and polygenic prediction of complex traits.        The American         Journal of Human Genetics, 2021.
1003 1004	[31]	Matthew A Reyna, Mark DM Leiserson, and Benjamin J Raphael. Hierarchical hotnet: identifying hierarchies of altered subnetworks. <u>Bioinformatics</u> , 34(17):i972–i980, 2018.
1005 1006 1007	[32]	Christopher C Chang, Carson C Chow, Laurent CAM Tellier, Shashaank Vattikuti, Shaun M Purcell, and James J Lee. Second-generation plink: rising to the challenge of larger and richer datasets. <u>Gigascience</u> , 4(1):s13742–015, 2015.
1008 1009	[33]	Gad Abraham, Yixuan Qiu, and Michael Inouye. Flashpca2: principal component analysis of biobank- scale genotype datasets. <u>Bioinformatics</u> , 2017.
1010 1011 1012	[34]	Gao Wang, Abhishek Sarkar, Peter Carbonetto, and Matthew Stephens. A simple new approach to variable selection in regression, with application to genetic fine mapping. <u>Journal of the Royal</u> <u>Statistical Society: Series B (Statistical Methodology)</u> , 82(5):1273–1300, 2020.
1013 1014	[35]	Huwenbo Shi, Steven Gazal, Masahiro Kanai, Evan M Koch, Armin P Schoech, Katherine M Siewert, Samuel S Kim, Yang Luo, Tiffany Amariuta, Hailiang Huang, et al. Population-specific causal disease

- effect sizes in functionally important regions impacted by selection. <u>Nature Communications</u>, 12(1): 1016 1–15, 2021.
- <sup>1017</sup> [36] Matthew Stephens. False discovery rates: a new deal. Biostatistics, 18(2):275–294, 2017.
- [37] Sarah M Urbut, Gao Wang, Peter Carbonetto, and Matthew Stephens. Flexible statistical methods
   for estimating and testing effects in genomic studies with multiple conditions. <u>Nature genetics</u>, 51(1):
   187–195, 2019.
- [38] Wei Cheng, Sohini Ramachandran, and Lorin Crawford. Estimation of non-null snp effect size dis tributions enables the detection of enriched genes underlying complex traits. <u>bioRxiv</u>, page 597484,
   2020.
- [39] Yan Zhang, Guanghao Qi, Ju-Hyun Park, and Nilanjan Chatterjee. Estimation of complex effect-size
   distributions using summary-level statistics from genome-wide association studies across 32 complex
   traits. Nature genetics, 50(9):1318–1326, 2018.
- [40] Michael C Wu, Seunggeun Lee, Tianxi Cai, Yun Li, Michael Boehnke, and Xihong Lin. Rare-variant
   association testing for sequencing data with the sequence kernel association test. <u>The American Journal</u>
   of Human Genetics, 89(1):82–93, 2011.
- [41] Priyanka Nakka, Benjamin J Raphael, and Sohini Ramachandran. Gene and network analysis of
   common variants reveals novel associations in multiple complex diseases. <u>Genetics</u>, 204(2):783–798,
   2016.
- [42] Alexander Gusev, Arthur Ko, Huwenbo Shi, Gaurav Bhatia, Wonil Chung, Brenda WJH Penninx,
   Rick Jansen, Eco JC De Geus, Dorret I Boomsma, Fred A Wright, et al. Integrative approaches for
   large-scale transcriptome-wide association studies. Nature genetics, 48(3):245, 2016.
- [43] Priyanka Nakka, Natalie P Archer, Heng Xu, Philip J Lupo, Benjamin J Raphael, Jun J Yang, and
   Sohini Ramachandran. Novel gene and network associations found for acute lymphoblastic leukemia
   using case-control and family-based studies in multiethnic populations. <u>Cancer Epidemiology and</u>
   Prevention Biomarkers, 26(10):1531–1539, 2017.
- [44] Antonio Fabregat, Konstantinos Sidiropoulos, Phani Garapati, Marc Gillespie, Kerstin Hausmann,
   Robin Haw, Bijay Jassal, Steven Jupe, Florian Korninger, Sheldon McKay, et al. The reactome
   pathway knowledgebase. Nucleic acids research, 44(D1):D481–D487, 2016.

- [45] Sabry Razick, George Magklaras, and Ian M Donaldson. irefindex: a consolidated protein interaction
   database with provenance. BMC bioinformatics, 9(1):405, 2008.
- <sup>1045</sup> [46] Jishnu Das and Haiyuan Yu. Hint: High-quality protein interactomes and their applications in under-<sup>1046</sup> standing human disease. BMC systems biology, 6(1):92, 2012.
- [47] Thomas Rolland, Murat Taşan, Benoit Charloteaux, Samuel J Pevzner, Quan Zhong, Nidhi Sahni,
   Song Yi, Irma Lemmens, Celia Fontanillo, Roberto Mosca, et al. A proteome-scale map of the human
   interactome network. Cell, 159(5):1212–1226, 2014.
- [48] Christopher S Carlson, Tara C Matise, Kari E North, Christopher A Haiman, Megan D Fesinmeyer,
   Steven Buyske, Fredrick R Schumacher, Ulrike Peters, Nora Franceschini, Marylyn D Ritchie, et al.
   Generalization and dilution of association results from european gwas in populations of non-european
   ancestry: the page study. PLoS Biol, 11(9):e1001661, 2013.
- [49] Jimmy Z Liu, Suzanne Van Sommeren, Hailiang Huang, Siew C Ng, Rudi Alberts, Atsushi Takahashi,
   Stephan Ripke, James C Lee, Luke Jostins, Tejas Shah, et al. Association analyses identify 38 sus ceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations.
   Nature genetics, 47(9):979, 2015.
- [50] Adam Eyre-Walker. Genetic architecture of a complex trait and its implications for fitness and genome wide association studies. <u>Proceedings of the National Academy of Sciences</u>, 107(suppl 1):1752–1756,
   2010.
- [51] Huwenbo Shi, Kathryn S Burch, Ruth Johnson, Malika K Freund, Gleb Kichaev, Nicholas Mancuso,
   Astrid M Manuel, Natalie Dong, and Bogdan Pasaniuc. Localizing components of shared transethnic
   genetic architecture of complex traits from gwas summary data. <u>The American Journal of Human</u>
   Genetics, 106(6):805–817, 2020.
- Image: AJ Szalai, J Wu, EM Lange, MA McCrory, CD Langefeld, A Williams, SO Zakharkin, Varghese
   George, DB Allison, GS Cooper, et al. Single-nucleotide polymorphisms in the c-reactive protein (crp)
   gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with
   differences in baseline serum crp level. Journal of Molecular Medicine, 83(6):440–447, 2005.
- [53] Shi-Chao Zhang, Ming-Yu Wang, Jun-Rui Feng, Yue Chang, Shang-Rong Ji, and Yi Wu. Reversible
   promoter methylation determines fluctuating expression of acute phase proteins. <u>Elife</u>, 9:e51317, 2020.
- <sup>1071</sup> [54] Farhad Hormozdiari, Emrah Kostem, Eun Yong Kang, Bogdan Pasaniuc, and Eleazar Eskin. Identi-<sup>1072</sup> fying causal variants at loci with multiple signals of association. Genetics, 198(2):497–508, 2014.

[55] Alicia R Martin, Meng Lin, Julie M Granka, Justin W Myrick, Xiaomin Liu, Alexandra Sockell,
 Elizabeth G Atkinson, Cedric J Werely, Marlo Möller, Manjinder S Sandhu, et al. An unexpectedly

<sup>1075</sup> complex architecture for skin pigmentation in africans. <u>Cell</u>, 171(6):1340–1353, 2017.

- <sup>1076</sup> [56] Brian L Browning and Sharon R Browning. Efficient multilocus association testing for whole genome as-
- sociation studies using localized haplotype clustering. <u>Genetic Epidemiology: The Official Publication</u>

of the International Genetic Epidemiology Society, 31(5):365–375, 2007.

- [57] Jimmy Z Liu, Allan F Mcrae, Dale R Nyholt, Sarah E Medland, Naomi R Wray, Kevin M Brown,
   Nicholas K Hayward, Grant W Montgomery, Peter M Visscher, Nicholas G Martin, et al. A versatile
   gene-based test for genome-wide association studies. <u>The American Journal of Human Genetics</u>, 87
   (1):139–145, 2010.
- [58] Christiaan A de Leeuw, Joris M Mooij, Tom Heskes, and Danielle Posthuma. Magma: generalized gene-set analysis of gwas data. PLoS Comput Biol, 11(4):e1004219, 2015.
- <sup>1085</sup> [59] Qian S Zhang, Brian L Browning, and Sharon R Browning. Genome-wide haplotypic testing in a <sup>1086</sup> finnish cohort identifies a novel association with low-density lipoprotein cholesterol. <u>European Journal</u> <sup>1087</sup> of Human Genetics, 23(5):672–677, 2015.
- [60] Xiang Zhu and Matthew Stephens. Bayesian large-scale multiple regression with summary statistics from genome-wide association studies. The annals of applied statistics, 11(3):1561, 2017.
- [61] John D Storey and Robert Tibshirani. Statistical significance for genomewide studies. <u>Proceedings of</u>
   the National Academy of Sciences, 100(16):9440–9445, 2003.
- [62] Benjamin M Neale, Sarah E Medland, Stephan Ripke, Philip Asherson, Barbara Franke, Klaus-Peter
   Lesch, Stephen V Faraone, Thuy Trang Nguyen, Helmut Schäfer, Peter Holmans, et al. Meta-analysis
   of genome-wide association studies of attention-deficit/hyperactivity disorder. Journal of the American
   Academy of Child & Adolescent Psychiatry, 49(9):884–897, 2010.
- [63] Ditte Demontis, Raymond K Walters, Joanna Martin, Manuel Mattheisen, Thomas D Als, Esben
   Agerbo, Gísli Baldursson, Rich Belliveau, Jonas Bybjerg-Grauholm, Marie Bækvad-Hansen, et al.
   Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder.
   Nature genetics, 51(1):63-75, 2019.
- [64] Mark D Leiserson, Fabio Vandin, Hsin-Ta Wu, Jason R Dobson, and Benjamin R Raphael. Pan-cancer
   identification of mutated pathways and protein complexes, 2014.

- [65] Lenore Cowen, Trey Ideker, Benjamin J Raphael, and Roded Sharan. Network propagation: a universal
   amplifier of genetic associations. Nature Reviews Genetics, 18(9):551, 2017.
- [66] Lucia A Hindorff, Vence L Bonham, Lawrence C Brody, Margaret EC Ginoza, Carolyn M Hutter,
   Teri A Manolio, and Eric D Green. Prioritizing diversity in human genomics research. <u>Nature Reviews</u>
- 1106 <u>Genetics</u>, 19(3):175, 2018.
- <sup>1107</sup> [67] Roseann E Peterson, Karoline Kuchenbaecker, Raymond K Walters, Chia-Yen Chen, Alice B Popejoy,
- Sathish Periyasamy, Max Lam, Conrad Iyegbe, Rona J Strawbridge, Leslie Brick, et al. Genome-wide
   association studies in ancestrally diverse populations: opportunities, methods, pitfalls, and recommen dations. Cell, 179(3):589–603, 2019.
- [68] Cristen J Willer, Yun Li, and Gonçalo R Abecasis. Metal: fast and efficient meta-analysis of genomewide association scans. Bioinformatics, 26(17):2190–2191, 2010.
- [69] Dan-Yu Lin, Ran Tao, William D Kalsbeek, Donglin Zeng, Franklyn Gonzalez II, Lindsay Fernández Rhodes, Mariaelisa Graff, Gary G Koch, Kari E North, and Gerardo Heiss. Genetic association analysis
   under complex survey sampling: the hispanic community health study/study of latinos. <u>The American</u>
   Journal of Human Genetics, 95(6):675–688, 2014.
- [70] Jian Yang, Noah A Zaitlen, Michael E Goddard, Peter M Visscher, and Alkes L Price. Advantages
  and pitfalls in the application of mixed-model association methods. <u>Nature genetics</u>, 46(2):100–106,
  2014.
- [71] Scott I Vrieze, William G Iacono, and Matt McGue. Confluence of genes, environment, development,
  and behavior in a post-gwas world. Development and Psychopathology, 24(4):1195, 2012.
- [72] Suzanne H Gage, George Davey Smith, Jennifer J Ware, Jonathan Flint, and Marcus R Munafo. G=
  e: What gwas can tell us about the environment. PLoS Genetics, 12(2):e1005765, 2016.
- [73] Luisa N. Borrell, Jennifer R. Elhawary, Elena Fuentes-Afflick, Jonathan Witonsky, Nirav Bhakta,
  Alan H.B. Wu, Kirsten Bibbins-Domingo, José R. RodrÃguez-Santana, Michael A. Lenoir, James R.
  Gavin, Rick A. Kittles, Noah A. Zaitlen, David S. Wilkes, Neil R. Powe, Elad Ziv, and Esteban G.
  Burchard. Race and genetic ancestry in medicine a time for reckoning with racism. <u>New England</u>
  Journal of Medicine, 0(0):null, 0. doi: 10.1056/NEJMms2029562. URL https://doi.org/10.1056/
  NEJMms2029562.

1130	[74] Alexander I Young, Michael L Frigge, Daniel F Gudbjartsson, Gudmar Thorleifsson, Gyda Bjornsdot-
1131	tir, Patrick Sulem, Gisli Masson, Unnur Thorsteinsdottir, Kari Stefansson, and Augustine Kong. Re-
1132	latedness disequilibrium regression estimates heritability without environmental bias. Nature genetics
1133	50(9):1304-1310, 2018.

- [75] Alexander I Young, Stefania Benonisdottir, Molly Przeworski, and Augustine Kong. Deconstructing
   the sources of genotype-phenotype associations in humans. Science, 365(6460):1396–1400, 2019.
- [76] Farhad Hormozdiari, Martijn Van De Bunt, Ayellet V Segre, Xiao Li, Jong Wha J Joo, Michael Bilow,
   Jae Hoon Sul, Sriram Sankararaman, Bogdan Pasaniuc, and Eleazar Eskin. Colocalization of gwas and
   eqtl signals detects target genes. The American Journal of Human Genetics, 99(6):1245–1260, 2016.
- [77] Nathan LaPierre, Kodi Taraszka, Helen Huang, Rosemary He, Farhad Hormozdiari, and Eleazar Eskin.
   Identifying causal variants by fine mapping across multiple studies. In <u>International Conference on</u>
   Research in Computational Molecular Biology, pages 257–258. Springer, 2020.
- [78] Lorin Crawford, Ping Zeng, Sayan Mukherjee, and Xiang Zhou. Detecting epistasis with the marginal
   epistasis test in genetic mapping studies of quantitative traits. <u>PLoS genetics</u>, 13(7):e1006869, 2017.
- [79] Michael C Turchin and Matthew Stephens. Bayesian multivariate reanalysis of large genetic studies
   identifies many new associations. PLoS genetics, 15(10):e1008431, 2019.
- [80] Xiang Zhou and Matthew Stephens. Genome-wide efficient mixed-model analysis for association studies. Nature genetics, 44(7):821–824, 2012.
- [81] Matthew Stephens. A unified framework for association analysis with multiple related phenotypes.
   PloS one, 8(7):e65245, 2013.
- [82] Brielin C Brown, Chun Jimmie Ye, Alkes L Price, Noah Zaitlen, Asian Genetic Epidemiology Network
   Type 2 Diabetes Consortium, et al. Transethnic genetic-correlation estimates from summary statistics.
   The American Journal of Human Genetics, 99(1):76–88, 2016.
- [83] Kevin J Galinsky, Yakir A Reshef, Hilary K Finucane, Po-Ru Loh, Noah Zaitlen, Nick J Patterson,
   Brielin C Brown, and Alkes L Price. Estimating cross-population genetic correlations of causal effect
   sizes. Genetic epidemiology, 43(2):180–188, 2019.
- [84] Barbara Domingues Bitarello and Iain Mathieson. Polygenic scores for height in admixed populations.
   bioRxiv, 2020.

- [85] Davide Marnetto, Katri Pärna, Kristi Läll, Ludovica Molinaro, Francesco Montinaro, Toomas Haller,
   Mait Metspalu, Reedik Mägi, Krista Fischer, and Luca Pagani. Ancestry deconvolution and par tial polygenic score can improve susceptibility predictions in recently admixed individuals. <u>Nature</u>
   communications, 11(1):1–9, 2020.
- [86] Hailiang Huang, Yunfeng Ruan, Yen-Chen Anne Feng, Chia-Yen Chen, Max Lam, Akira Sawa, Alicia
   Martin, Shengying Qin, and Tian Ge. Improving polygenic prediction in ancestrally diverse popula tions. 2021.
- [87] Laura K Hayward and Guy Sella. Polygenic adaptation after a sudden change in environment. <u>BioRxiv</u>,
   page 792952, 2019.
- [88] Jon McClellan and Mary-Claire King. Genetic heterogeneity in human disease. <u>Cell</u>, 141(2):210–217,
  2010.
- <sup>1169</sup> [89] Farid Rajabli, Briseida E Feliciano, Katrina Celis, Kara L Hamilton-Nelson, Patrice L Whitehead,
- Larry D Adams, Parker L Bussies, Clara P Manrique, Alejandra Rodriguez, Vanessa Rodriguez, et al. Ancestral origin of apoe  $\varepsilon 4$  alzheimer disease risk in puerto rican and african american populations. PLoS genetics, 14(12), 2018.
- [90] Jake R Conway, Alexander Lex, and Nils Gehlenborg. Upsetr: an r package for the visualization of intersecting sets and their properties. Bioinformatics, 33(18):2938–2940, 2017.
- [91] David H Alexander, John Novembre, and Kenneth Lange. Fast model-based estimation of ancestry in unrelated individuals. Genome research, 19(9):1655–1664, 2009.
- [92] Peter H Sudmant, Tobias Rausch, Eugene J Gardner, Robert E Handsaker, Alexej Abyzov, John
  Huddleston, Yan Zhang, Kai Ye, Goo Jun, Markus Hsi-Yang Fritz, et al. An integrated map of
  structural variation in 2,504 human genomes. Nature, 526(7571):75-81, 2015.
- [93] Masahiro Kanai, Masato Akiyama, Atsushi Takahashi, Nana Matoba, Yukihide Momozawa, Masashi
  Ikeda, Nakao Iwata, Shiro Ikegawa, Makoto Hirata, Koichi Matsuda, et al. Genetic analysis of quantitative traits in the japanese population links cell types to complex human diseases. <u>Nature genetics</u>,
  50(3):390–400, 2018.
- [94] Masato Akiyama, Yukinori Okada, Masahiro Kanai, Atsushi Takahashi, Yukihide Momozawa, Masashi
  Ikeda, Nakao Iwata, Shiro Ikegawa, Makoto Hirata, Koichi Matsuda, et al. Genome-wide association
  study identifies 112 new loci for body mass index in the japanese population. <u>Nature genetics</u>, 49(10):
  1458, 2017.

- [95] Masato Akiyama, Kazuyoshi Ishigaki, Saori Sakaue, Yukihide Momozawa, Momoko Horikoshi, Makoto
  Hirata, Koichi Matsuda, Shiro Ikegawa, Atsushi Takahashi, Masahiro Kanai, et al. Characterizing rare
  and low-frequency height-associated variants in the japanese population. <u>Nature communications</u>, 10
  (1):1–11, 2019.
- [96] Derek Klarin, Scott M Damrauer, Kelly Cho, Yan V Sun, Tanya M Teslovich, Jacqueline Honerlaw,
  David R Gagnon, Scott L DuVall, Jin Li, Gina M Peloso, et al. Genetics of blood lipids among<sup>~</sup>
  300,000 multi-ethnic participants of the million veteran program. <u>Nature genetics</u>, 50(11):1514–1523,
  2018.
- [97] Paul S De Vries, Michael R Brown, Amy R Bentley, Yun J Sung, Thomas W Winkler, Ioanna Ntalla,
  Karen Schwander, Aldi T Kraja, Xiuqing Guo, Nora Franceschini, et al. Multiancestry genomewide association study of lipid levels incorporating gene-alcohol interactions. <u>American journal of</u>
  epidemiology, 188(6):1033–1054, 2019.
- [98] Raymond Noordam, Maxime M Bos, Heming Wang, Thomas W Winkler, Amy R Bentley, Tuomas O
   Kilpeläinen, Paul S de Vries, Yun Ju Sung, Karen Schwander, Brian E Cade, et al. Multi-ancestry
   sleep-by-snp interaction analysis in 126,926 individuals reveals lipid loci stratified by sleep duration.
   Nature communications, 10(1):1–13, 2019.
- [99] Tom G Richardson, Eleanor Sanderson, Tom M Palmer, Mika Ala-Korpela, Brian A Ference, George
   Davey Smith, and Michael V Holmes. Evaluating the relationship between circulating lipoprotein lipids
   and apolipoproteins with risk of coronary heart disease: A multivariable mendelian randomisation
   analysis. PLoS medicine, 17(3):e1003062, 2020.
- [100] Thomas J Hoffmann, Elizabeth Theusch, Tanushree Haldar, Dilrini K Ranatunga, Eric Jorgenson,
   Marisa W Medina, Mark N Kvale, Pui-Yan Kwok, Catherine Schaefer, Ronald M Krauss, et al. A
   large electronic-health-record-based genome-wide study of serum lipids. <u>Nature genetics</u>, 50(3):401–
   413, 2018.
- [101] Alexander M Kulminski, Jian Huang, Yury Loika, Konstantin G Arbeev, Olivia Bagley, Arseniy
   Yashkin, Matt Duan, and Irina Culminskaya. Strong impact of natural-selection—free heterogeneity in
   genetics of age-related phenotypes. Aging (Albany NY), 10(3):492, 2018.
- [102] Aldi T Kraja, Dhananjay Vaidya, James S Pankow, Mark O Goodarzi, Themistocles L Assimes,
   Iftikhar J Kullo, Ulla Sovio, Rasika A Mathias, Yan V Sun, Nora Franceschini, et al. A bivariate

<sup>1217</sup> genome-wide approach to metabolic syndrome: Stampeed consortium. <u>Diabetes</u>, 60(4):1329–1339, <sup>1218</sup> 2011.

[103] Cassandra N Spracklen, Peng Chen, Young Jin Kim, Xu Wang, Hui Cai, Shengxu Li, Jirong Long,
 Ying Wu, Ya Xing Wang, Fumihiko Takeuchi, et al. Association analyses of east asian individuals
 and trans-ancestry analyses with european individuals reveal new loci associated with cholesterol and
 triglyceride levels. Human molecular genetics, 26(9):1770–1784, 2017.

[104] Makoto Kurano, Kazuhisa Tsukamoto, Shigeo Kamitsuji, Naoyuki Kamatani, Masumi Hara, Toshio
 Ishikawa, Bong-Jo Kim, Sanghoon Moon, Young Jin Kim, and Tamio Teramoto. Genome-wide association study of serum lipids confirms previously reported associations as well as new associations of
 common snps within pcsk7 gene with triglyceride. Journal of human genetics, 61(5):427–433, 2016.

[105] Amy R Bentley, Yun J Sung, Michael R Brown, Thomas W Winkler, Aldi T Kraja, Ioanna Ntalla,
 Karen Schwander, Daniel I Chasman, Elise Lim, Xuan Deng, et al. Multi-ancestry genome-wide
 gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids.
 Nature genetics, 51(4):636–648, 2019.

- [106] Ida Surakka, Momoko Horikoshi, Reedik Mägi, Antti-Pekka Sarin, Anubha Mahajan, Vasiliki Lagou,
   Letizia Marullo, Teresa Ferreira, Benjamin Miraglio, Sanna Timonen, et al. The impact of low frequency and rare variants on lipid levels. Nature genetics, 47(6):589–597, 2015.
- [107] Tanya M Teslovich, Kiran Musunuru, Albert V Smith, Andrew C Edmondson, Ioannis M Stylianou,
   Masahiro Koseki, James P Pirruccello, Samuli Ripatti, Daniel I Chasman, Cristen J Willer, et al.
   Biological, clinical and population relevance of 95 loci for blood lipids. <u>Nature</u>, 466(7307):707–713,
   2010.
- [108] Anders Bergström, Shane A McCarthy, Ruoyun Hui, Mohamed A Almarri, Qasim Ayub, Petr Danecek,
   Yuan Chen, Sabine Felkel, Pille Hallast, Jack Kamm, et al. Insights into human genetic variation and
   population history from 929 diverse genomes. Science, 367(6484), 2020.
- [109] Peter Carbonetto and Matthew Stephens. Integrated enrichment analysis of variants and pathways in
   genome-wide association studies indicates central role for il-2 signaling genes in type 1 diabetes, and
   cytokine signaling genes in crohn's disease. PLoS genetics, 9(10):e1003770, 2013.
- <sup>1244</sup> [110] Xiang Zhu and Matthew Stephens. Large-scale genome-wide enrichment analyses identify new trait-<sup>1245</sup> associated genes and pathways across 31 human phenotypes. <u>Nature communications</u>, 9(1):1–14, 2018.

- [111] Michael C Wu, Peter Kraft, Michael P Epstein, Deanne M Taylor, Stephen J Chanock, David J
   Hunter, and Xihong Lin. Powerful snp-set analysis for case-control genome-wide association studies.
   The American Journal of Human Genetics, 86(6):929–942, 2010.
- [112] Seunggeun Lee, Mary J Emond, Michael J Bamshad, Kathleen C Barnes, Mark J Rieder, Deborah A
   Nickerson, ESP Lung Project Team, David C Christiani, Mark M Wurfel, Xihong Lin, et al. Opti mal unified approach for rare-variant association testing with application to small-sample case-control
   whole-exome sequencing studies. The American Journal of Human Genetics, 91(2):224–237, 2012.
- [113] Iuliana Ionita-Laza, Seunggeun Lee, Vlad Makarov, Joseph D Buxbaum, and Xihong Lin. Sequence
   kernel association tests for the combined effect of rare and common variants. <u>The American Journal</u>
   of Human Genetics, 92(6):841–853, 2013.
- [114] Melissa R McGuirl, Samuel Pattillo Smith, Björn Sandstede, and Sohini Ramachandran. Detecting
   shared genetic architecture among multiple phenotypes by hierarchical clustering of gene-level association statistics. Genetics, 2020.
- <sup>1259</sup> [115] Maria Maddalena Barbieri, James O Berger, et al. Optimal predictive model selection. <u>The annals of</u> statistics, 32(3):870–897, 2004.
- [116] Terhi Kettunen, Carita Eklund, Mika Kähönen, Antti Jula, Hannu Päivä, Leo-Pekka Lyytikäinen,
   Mikko Hurme, and Terho Lehtimäki. Polymorphism in the c-reactive protein (crp) gene affects crp
   levels in plasma and one early marker of atherosclerosis in men: The health 2000 survey. <u>Scandinavian</u>
   journal of clinical and laboratory investigation, 71(5):353–361, 2011.
- [117] Amy Z Fan, Ajay Yesupriya, Man-huei Chang, Meaghan House, Jing Fang, Renée Ned, Donald Hayes,
   Nicole F Dowling, and Ali H Mokdad. Gene polymorphisms in association with emerging cardiovascular
   risk markers in adult women. BMC medical genetics, 11(1):6, 2010.
- [118] E Komurcu-Bayrak, N Erginel-Unaltuna, A Onat, B Ozsait, C Eklund, M Hurme, N Mononen, R Laak sonen, G Hergenc, and T Lehtimäki. Association of c-reactive protein (crp) gene allelic variants with
   serum crp levels and hypertension in turkish adults. <u>Atherosclerosis</u>, 206(2):474–479, 2009.
- [119] S-N Chang, C-T Tsai, C-K Wu, J-K Lee, L-P Lai, S-W Huang, L-Y Huang, C-D Tseng, J-L Lin, F-T
  Chiang, et al. A functional variant in the promoter region regulates the c-reactive protein gene and
  is a potential candidate for increased risk of atrial fibrillation. Journal of internal medicine, 272(3):
  305–315, 2012.

[120] Hyoun-Ah Kim, Hye-Young Chun, Seung-Hyun Kim, Hae-Sim Park, and Chang-Hee Suh. C-reactive
 protein gene polymorphisms in disease susceptibility and clinical manifestations of korean systemic
 lupus erythematosus. The Journal of rheumatology, 36(10):2238–2243, 2009.

[121] Abbas Dehghan, Josée Dupuis, Maja Barbalic, Joshua C Bis, Gudny Eiriksdottir, Chen Lu, Niina Pellikka, Henri Wallaschofski, Johannes Kettunen, Peter Henneman, et al. Meta-analysis of genome-wide
association studies in; 80 000 subjects identifies multiple loci for c-reactive protein levels. <u>Circulation</u>,
123(7):731–738, 2011.

[122] Paul M Ridker, Guillaume Pare, Alex Parker, Robert YL Zee, Jacqueline S Danik, Julie E Buring,
David Kwiatkowski, Nancy R Cook, Joseph P Miletich, and Daniel I Chasman. Loci related to
metabolic-syndrome pathways including lepr, hnf1a, il6r, and gckr associate with plasma c-reactive
protein: the women's genome health study. <u>The American Journal of Human Genetics</u>, 82(5):1185–
1192, 2008.

- [123] Symen Ligthart, Ahmad Vaez, Urmo Võsa, Maria G Stathopoulou, Paul S De Vries, Bram P Prins, Peter J Van der Most, Toshiko Tanaka, Elnaz Naderi, Lynda M Rose, et al. Genome analyses of; 200,000
   individuals identify 58 loci for chronic inflammation and highlight pathways that link inflammation
   and complex disorders. The American Journal of Human Genetics, 103(5):691–706, 2018.
- [124] Alex P Reiner, Sandra Beleza, Nora Franceschini, Paul L Auer, Jennifer G Robinson, Charles Kooper berg, Ulrike Peters, and Hua Tang. Genome-wide association and population genetic analysis of
   c-reactive protein in african american and hispanic american women. <u>The American Journal of Human</u>
   Genetics, 91(3):502–512, 2012.
- [125] Paul Elliott, John C Chambers, Weihua Zhang, Robert Clarke, Jemma C Hopewell, John F Peden,
   Jeanette Erdmann, Peter Braund, James C Engert, Derrick Bennett, et al. Genetic loci associated
   with c-reactive protein levels and risk of coronary heart disease. Jama, 302(1):37–48, 2009.

[126] Deog Kyeom Kim, Michael H Cho, Craig P Hersh, David A Lomas, Bruce E Miller, Xiangyang Kong,
 Per Bakke, Amund Gulsvik, Alvar Agustí, Emiel Wouters, et al. Genome-wide association analysis
 of blood biomarkers in chronic obstructive pulmonary disease. <u>American journal of respiratory and</u>
 critical care medicine, 186(12):1238–1247, 2012.

[127] William J Astle, Heather Elding, Tao Jiang, Dave Allen, Dace Ruklisa, Alice L Mann, Daniel Mead,
 Heleen Bouman, Fernando Riveros-Mckay, Myrto A Kostadima, et al. The allelic landscape of human
 blood cell trait variation and links to common complex disease. Cell, 167(5):1415–1429, 2016.

[128] Juraj Sokol, Kamil Biringer, Maria Skerenova, Miroslav Hasko, Lenka Bartosova, Jan Stasko, Jan
 Danko, and Peter Kubisz. Platelet aggregation abnormalities in patients with fetal losses: the gp6
 gene polymorphism. Fertility and sterility, 98(5):1170–1174, 2012.

[129] Andrew D Johnson, Lisa R Yanek, Ming-Huei Chen, Nauder Faraday, Martin G Larson, Geoffrey
 Tofler, Shiow J Lin, Aldi T Kraja, Michael A Province, Qiong Yang, et al. Genome-wide meta-analyses
 identifies seven loci associated with platelet aggregation in response to agonists. <u>Nature genetics</u>, 42
 (7):608–613, 2010.

[130] Takao Shimizu. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets
 for the regulation of immunity and inflammation. <u>Annual review of pharmacology and toxicology</u>, 49:
 123–150, 2009.

[131] Yuji Shimizu, Kazuhiko Arima, Yuko Noguchi, Shin-Ya Kawashiri, Hirotomo Yamanashi, Mami Tamai,
 Yasuhiro Nagata, and Takahiro Maeda. Potential mechanisms underlying the association between
 single nucleotide polymorphism (brap and aldh2) and hypertension among elderly japanese population.
 Scientific Reports, 10(1):1–9, 2020.

- [132] John D Eicher, Nathalie Chami, Tim Kacprowski, Akihiro Nomura, Ming-Huei Chen, Lisa R Yanek,
   Salman M Tajuddin, Ursula M Schick, Andrew J Slater, Nathan Pankratz, et al. Platelet-related
   variants identified by exomechip meta-analysis in 157,293 individuals. <u>The American Journal of Human</u>
   Genetics, 99(1):40-55, 2016.
- [133] Rehan Qayyum, Beverly M Snively, Elad Ziv, Michael A Nalls, Yongmei Liu, Weihong Tang, Lisa R
  Yanek, Leslie Lange, Michele K Evans, Santhi Ganesh, et al. A meta-analysis and genome-wide
  association study of platelet count and mean platelet volume in african americans. <u>PLoS Genet</u>, 8(3):
  e1002491, 2012.
- [134] Cristen J Willer, Ellen M Schmidt, Sebanti Sengupta, Gina M Peloso, Stefan Gustafsson, Stavroula
   Kanoni, Andrea Ganna, Jin Chen, Martin L Buchkovich, Samia Mora, et al. Discovery and refinement
   of loci associated with lipid levels. Nature genetics, 45(11):1274, 2013.
- [135] Rita PS Middelberg, Manuel AR Ferreira, Anjali K Henders, Andrew C Heath, Pamela AF Madden,
   Grant W Montgomery, Nicholas G Martin, and John B Whitfield. Genetic variants in lpl, oasl and
   tomm40/apoe-c1-c2-c4 genes are associated with multiple cardiovascular-related traits. <u>BMC medical</u>
   genetics, 12(1):123, 2011.

[136] Sekar Kathiresan, Olle Melander, Candace Guiducci, Aarti Surti, Noël P Burtt, Mark J Rieder, Gregory M Cooper, Charlotta Roos, Benjamin F Voight, Aki S Havulinna, et al. Six new loci associated
with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in
humans. Nature genetics, 40(2):189–197, 2008.

[137] Jaspal S Kooner, John C Chambers, Carlos A Aguilar-Salinas, David A Hinds, Craig L Hyde, Gregory R Warnes, Francisco J Gómez Pérez, Kelly A Frazer, Paul Elliott, James Scott, et al. Genomewide scan identifies variation in mlxipl associated with plasma triglycerides. <u>Nature genetics</u>, 40(2):
149, 2008.

[138] Sekar Kathiresan, Cristen J Willer, Gina M Peloso, Serkalem Demissie, Kiran Musunuru, Eric E
 Schadt, Lee Kaplan, Derrick Bennett, Yun Li, Toshiko Tanaka, et al. Common variants at 30 loci
 contribute to polygenic dyslipidemia. Nature genetics, 41(1):56–65, 2009.

[139] Maria Keller, Dorit Schleinitz, Julia Förster, Anke Tönjes, Yvonne Böttcher, Antje Fischer-Rosinsky,
 Jana Breitfeld, Kerstin Weidle, Nigel W Rayner, Ralph Burkhardt, et al. Thoc5: a novel gene involved
 in hdl-cholesterol metabolism. Journal of lipid research, 54(11):3170–3176, 2013.

[140] Richa Saxena, Benjamin F Voight, Valeriya Lyssenko, Noël P Burtt, Paul IW de Bakker, Hong Chen,
 Jeffrey J Roix, Sekar Kathiresan, Joel N Hirschhorn, Mark J Daly, et al. Genome-wide association
 analysis identifies loci for type 2 diabetes and triglyceride levels. Science, 316(5829):1331–1336, 2007.

1351 [141] Yurii S Aulchenko, Samuli Ripatti, Ida Lindqvist, Dorret Boomsma, Iris M Heid, Peter P Pramstaller,

- Brenda WJH Penninx, A Cecile JW Janssens, James F Wilson, Tim Spector, et al. Loci influencing
  lipid levels and coronary heart disease risk in 16 european population cohorts. <u>Nature genetics</u>, 41(1):
  47, 2009.
- [142] Rubina Tabassum, Joel T Rämö, Pietari Ripatti, Jukka T Koskela, Mitja Kurki, Juha Karjalainen,
   Priit Palta, Shabbeer Hassan, Javier Nunez-Fontarnau, Tuomo TJ Kiiskinen, et al. Genetic architecture
   of human plasma lipidome and its link to cardiovascular disease. <u>Nature communications</u>, 10(1):1–14,
   2019.
- [143] Liang He, Yelena Kernogitski, Irina Kulminskaya, Yury Loika, Konstantin G Arbeev, Elena Loiko,
   Olivia Bagley, Matt Duan, Arseniy Yashkin, Svetlana V Ukraintseva, et al. Pleiotropic meta-analyses
   of longitudinal studies discover novel genetic variants associated with age-related diseases. Frontiers
   in genetics, 7:179, 2016.

[144] Dawn M Waterworth, Sally L Ricketts, Kijoung Song, Li Chen, Jing Hua Zhao, Samuli Ripatti, Yurii S
 Aulchenko, Weihua Zhang, Xin Yuan, Noha Lim, et al. Genetic variants influencing circulating lipid
 levels and risk of coronary artery disease. <u>Arteriosclerosis, thrombosis, and vascular biology</u>, 30(11):
 2264–2276, 2010.

[145] Gina M Peloso, Paul L Auer, Joshua C Bis, Arend Voorman, Alanna C Morrison, Nathan O Stitziel,
 Jennifer A Brody, Sumeet A Khetarpal, Jacy R Crosby, Myriam Fornage, et al. Association of low frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000
 whites and blacks. The American Journal of Human Genetics, 94(2):223–232, 2014.

<sup>1371</sup> [146] Tuomas O Kilpeläinen, Amy R Bentley, Raymond Noordam, Yun Ju Sung, Karen Schwander,
 <sup>1372</sup> Thomas W Winkler, Hermina Jakupović, Daniel I Chasman, Alisa Manning, Ioanna Ntalla, et al.
 <sup>1373</sup> Multi-ancestry study of blood lipid levels identifies four loci interacting with physical activity. <u>Nature</u>
 <sup>1374</sup> communications, 10(1):1–11, 2019.

- [147] Yoichiro Kamatani, Koichi Matsuda, Yukinori Okada, Michiaki Kubo, Naoya Hosono, Yataro Daigo,
   Yusuke Nakamura, and Naoyuki Kamatani. Genome-wide association study of hematological and
   biochemical traits in a japanese population. Nature genetics, 42(3):210, 2010.
- [148] Marc A Coram, Qing Duan, Thomas J Hoffmann, Timothy Thornton, Joshua W Knowles, Nicholas A
  Johnson, Heather M Ochs-Balcom, Timothy A Donlon, Lisa W Martin, Charles B Eaton, et al.
  Genome-wide characterization of shared and distinct genetic components that influence blood lipid
  levels in ethnically diverse human populations. <u>The American Journal of Human Genetics</u>, 92(6):
  904–916, 2013.

[149] Deepti Gurdasani, Tommy Carstensen, Segun Fatumo, Guanjie Chen, Chris S Franklin, Javier Prado Martinez, Heleen Bouman, Federico Abascal, Marc Haber, Ioanna Tachmazidou, et al. Uganda genome
 resource enables insights into population history and genomic discovery in africa. <u>Cell</u>, 179(4):984–1002,
 2019.

- [150] Elisabeth M van Leeuwen, Aniko Sabo, Joshua C Bis, Jennifer E Huffman, Ani Manichaikul, Albert V
  Smith, Mary F Feitosa, Serkalem Demissie, Peter K Joshi, Qing Duan, et al. Meta-analysis of 49
  549 individuals imputed with the 1000 genomes project reveals an exonic damaging variant in angptl4
  determining fasting tg levels. Journal of medical genetics, 53(7):441–449, 2016.
- <sup>1391</sup> [151] Robert Perneczky, Panagiotis Alexopoulos, and Alzheimer's Disease euroimaging Initiative. Cere-

- <sup>1392</sup> brospinal fluid bace1 activity and markers of amyloid precursor protein metabolism and axonal degen-
- eration in alzheimer's disease. Alzheimer's & Dementia, 10:S425–S429, 2014.
- <sup>1394</sup> [152] Christoph Heiring, Björn Dahlbäck, and Yves A Muller. Ligand recognition and homophilic interactions
- in tyro3 structural insights into the axl/tyro3 receptor tyrosine kinase family. Journal of Biological
- <sup>1396</sup> Chemistry, 279(8):6952–6958, 2004.